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ABSTRACT OF THE DISSERTATION
UNDERSTANDING TEN-ELEVEN TRANSLOCATION-2 IN HEMATOLOGICAL
AND NERVOUS SYSTEMS
by
Feng Pan
Florida International University, 2015
Miami, Florida
Professor Ophelia Weeks, Co-Major Professor
Associate Professor Lidia Kos, Co-Major Professor
I proposed the study of two distinct aspects of Ten-Eleven Translocation 2 (TET2)
protein for understanding specific functions in different body systems.
In Part I, I characterized the molecular mechanisms of Tet2 in the hematological
system. As the second member of Ten-Eleven Translocation protein family, TET2 is
frequently mutated in leukemic patients. Previous studies have shown that the TET2
mutations frequently occur in 20% myelodysplastic syndrome/myeloproliferative
neoplasm (MDS/MPN), 10% T-cell lymphoma leukemia and 2% B-cell lymphoma
leukemia. Genetic mouse models also display distinct phenotypes of various types of
hematological malignancies. I performed 5-hydroxymethylcytosine (5hmC) chromatin
immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq) of
hematopoietic stem/progenitor cells to determine whether the deletion of Tet2 can affect
the abundance of 5hmC at myeloid, T-cell and B-cell specific gene transcription start
sites, which ultimately result in various hematological malignancies. Subsequent Exome
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sequencing (Exome-Seq) showed that disease-specific genes are mutated in different
types of tumors, which suggests that TET2 may protect the genome from being mutated.
The direct interaction between TET2 and Mutator S Homolog 6 (MSH6) protein suggests
TET2 is involved in DNA mismatch repair. Finally, in vivo mismatch repair studies show
that the loss of Tet2 causes a mutator phenotype. Taken together, my data indicate that
TET2 binds to MSH6 to protect genome integrity.
In Part II, I intended to better understand the role of Tet2 in the nervous system. 5hydroxymethylcytosine regulates epigenetic modification during neurodevelopment and
aging. Thus, Tet2 may play a critical role in regulating adult neurogenesis. To examine
the physiological significance of Tet2 in the nervous system, I first showed that the
deletion of Tet2 reduces the 5hmC levels in neural stem cells. Mice lacking Tet2 show
abnormal hippocampal neurogenesis along with 5hmC alternations at different gene
promoters and corresponding gene expression downregulation. Through the luciferase
reporter assay, two neural factors Neurogenic differentiation 1 (NeuroD1) and Glial
fibrillary acidic protein (Gfap) were down-regulated in Tet2 knockout cells. My results
suggest that Tet2 regulates neural stem/progenitor cell proliferation and differentiation in
adult brain.
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CHAPTER
INTRODUCTION

1

1.1 DNA METHYLATION AND DEMETHYLATION
Epigenetics, proposed by Waddington in 1942, is broadly defined and attributed to
heritable cellular changes without altering the deoxyribonucleic acid (DNA) sequence1,2.
Molecular mechanisms of epigenetic regulation include: DNA methylation, histone
modifications and noncoding regulatory ribonucleic acids (RNAs). DNA methylation on
cytosine-phosphate-guanine (CpG) islands at promoter regions is considered as one stable
epigenetic mark3 and such DNA alternation is sufficient to maintain genome imprinting
and X-chromosome inactivation4. Deoxyribonucleic acid methylation also occurs in other
genomic elements such as gene body, enhancer and untranslated regions (UTR). It may
contribute to transcription elongation or gene activation/inactivation5. Histone
modifications widely exist posttranslationally, and include lysine and arginine
methylation, lysine acetylation, ubiquitination and sumoylation, as well as serine and
threonine phosphorylation6. These modifications regulate gene expression and are
responsible for the presence of enhancers or repressors6,7. In mammalian cells,
microRNAs regulate gene expression by posttranslational repression of target sequences.
Since the expression of microRNAs is also affected by their promoter status, the
transcriptional regulation by microRNAs is relatively mild8. In recent years, studies on
hematological malignancies have revealed a subset of epigenetic regulators as cancerrelevant genes. The corresponding epigenetic alterations lead to changes in specific gene
transcriptions, which finally result in abnormal hematopoietic stem cells (HSC) and/or
hematopoietic progenitor cells (HPC) self-renewal, proliferation and differentiation.
Methylation of DNA normally indicates modification of cytosine. In mammals, the
DNA methyltransferase (DNMT) family comprises five members: DNMT1, DNMT2,
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DNMT3A, DNMT3B and DNMT3L. The enzyme DNA methyltransferase 1 (DNMT1)
maintains cytosine hemimethylated during DNA replication9 (Figure 1). DNA
methyltransferase 2 (DNMT2), also termed TRDMT1, is the smallest DNMT whose
function is still poorly understood, but the specific protein structure of DNMT2 suggests
the possibility of involvement in DNA recombination and DNA damage repair10.
Deoxyribonucleic acid methyltransferase 3 has two family members: DNMT3A and
DNMT3B which control de novo cytosine methylation of unmethylated DNA substrates11
(Figure 1). However, their enzymatic activities can be negatively regulated by DNMT3L,
which functions mainly during early embryogenesis12,13.
The human genome contains around 28 million CpGs while the mouse genome has
approximately 22 million CpGs. These CpGs reside in different genomic elements such
as CpG islands (CGIs), gene bodies and enhancers. Only around 20% of CpGs are
dynamic, most of the CpGs are relatively stable14,15. Genome-wide methylation studies
have revealed detailed architectural profiles for DNA methylation at gene bodies, CGIs,
CGI shore, enhancers, canyons, repeats and large differentially methylated regions
(DMR)16 (Figure 2). Cytosine-phosphate-guanine islands are defined as short and CpGrich regions within the genome, and more than 70% of genes have CGIs17. When CGIs
are unmethylated at the promoter region, that usually signifies transcription initiation in
nucleosome-free style, in which the transcriptional levels are regulated by Histone H3
lysine4 tri-methylation and transcription factors association. Whereas, methylation at
CGIs may signify long-term gene silencing, as occurs in imprinted genes18,19.
Recently, genome-wide methylome studies have allowed scientists to examine DNA
methylation status outside promoter CGIs in both stem and differentiated cells. It has
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been reported that tissue- or cancer-specific differentially methylated regions within CGI
shores are more dynamic than those regions within CGIs16. Thus, it is plausible to
propose that the methylation status at CGI shores may be involved in epigenetic
reprogramming and cancer20. Actually, many genes in lymphoid- or myeloid-specific
lineages show frequent methylation changes in CGI shores during cell differentiation21.
DNA methylation also occurs in intergenic regions, but little is known about its
physiological function. As a critical genetic element, most enhancers reside in such
regions. Studies suggest that cell-specific transcription is closely associated with
enhancer methylation levels even if the relevant promoter stays unmethylated. Through
binding to chromatin modulating factors, these enhancers are able to interact with distal
promoters, which result in specific DNA methylation patterns in different cell types22.
Genome-wide methylome studies also identify a bunch of differential methylated regions
that are enriched at different cellular stages during hematopoiesis and these regions are
demonstrated as transcription factor binding sites. Interestingly, in lymphoid
stem/progenitor cells, myeloid transcription factor binding sites are hypomethylated.
Whereas during lymphoid differentiation, myeloid-specific factors binding sites are
hypermethylated23.
In addition, large hypomethylated regions have been identified serendipitously,
during the process of comparing 5mC abundance in differentiated fibroblasts and human
embryonic stem cells24. These large canyon regions usually spin at 1Mb, and include
certain oncogenes and cancer biomarker genes25. The loss of DNA methylation in these
regions leads to repressive histone mark acquisition and gene downregulation26.
Moreover, methylation canyons are found in regions with very low levels of methylation
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in hematopoietic stem cells27. The loss of DNMT3A causes DNA methylation alterations
at the edge of canyons28. The methylation changes in canyons may result in transcription
alteration and genomic instability that contribute to the progression of cancer.
In addition to being in promoter regions, CGIs are also found within gene bodies16.
Even though there is a small amount of evidence that gene body methylation correlates
with gene transcription repression, the opposite, gene transcription activation has been
proposed29. Indeed, actively transcribed genes have been identified as hypermethylated in
the gene bodies16. Several studies infer that gene body methylation regions are the
enhancer sites or regulate tissue-specific gene transcription from promoters. Besides,
DNA methylation at gene bodies may also facilitate the recruitment of CpG binding
proteins and prevent CCCTC-binding factor mediated RNA polymerase II stalling and
spliceosome assembly30-33. Obviously, gene body methylation and promoter methylation
play distinct roles in transcription regulation. But, the underlying mechanism of gene
body methylation still needs to be elucidated in the future16.
There are also specific genomic regions called repetitive elements with multiple
copies in the genome. Methylation of repetitive elements may repress the expression of
transposable elements in order to maintain genome integrity34. Bisulfite sequencing from
DNMT3B mutant patients exhibit significant changes of DNA methylation in inactive
heterochromatic regions, satellite repeats and transposons. And, aberrant expression
levels of key genes may result from hypomethylation of repetitive elements, even though
ribosomal RNA repeats are free from global hypomethylation35. As the most abundant
genes in the genome, ribosomal DNA stays in tandem repetitive clusters. The
hematopoietic progenitor cells from MDS patients harbor increased ribosomal DNA
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(rDNA) methylation levels with decreased ribosomal RNA (rRNA) expression compared
to healthy controls35. When myeloid cells are treated with 5-Aza-2′-deoxycytidine,
significant methylation decrease at rDNA promoter regions is observed along with
increased rRNA levels36.
It has been reported that about 80% of CpGs are methylated in mammalian genome,
which suggest a relatively stable pattern of DNA methylation in the genome. However,
DNA methylation can be erased passively or actively through different demethylation
pathways. Passive demethylation initiates through the inactivation of DNMT1/3
(downregulation of gene expression, genetic mutations or inhibitors). The methylation of
a newly synthesized DNA strand is blocked during DNA replication. Other studies have
demonstrated that DNA methylation patterns can be further modified by active
demethylation. Active demethylation is mediated by TET family enzymes, which
catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC)
and further 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in this pathway37-39
(Figure 1).
On the basis of DNA semiconservative replication mechanism, the relative amount
of DNA methylation is half diluted when new DNA strands are synthesized. Thus, the
methylation status at specific gene loci will disappear in daughter cells upon cell
divisions. The above phenotype is the so-called “passive DNA demethylation”40 (Figure
1). However, how “active DNA demethylation” initiates is still less understood. Yet, the
identification of 5mC glycosylases in plants has thrown some light on the process, since
there is a similar occurrence in mammalian cells during zygote fertilization40,41. In
primordial germ cells (PGCs), genome-wide erasure of DNA methylation occurs
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naturally42. It is believed that active DNA demethylation preferentially happens at the
specific loci in differentiated somatic cells43. Studies on identification of DNA
demethylases have greatly increased in recent years. Methyl-CpG binding domain protein
2 (MBD2) binds the promoter region enriched in CpG and functions as a mediator of
methylation signals to activate gene transcription44. Additional studies have shown that
mammalian thymine DNA glycosylase (TDG) catalyzes the glycosylation of 5mC,
eventhough no in vivo data have verified the exact role of TDG in DNA demethylation45.
But, several potential mechanisms have also been proposed to better explain DNA
demethylation. These include deamination by activation-induced deaminases (AID), and
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) protein
deaminases or DNMTs. Briefly, generated T:G mismatch leads to the initiation of base
excision repair (BER) and a series of enzymes facilitate the refill of unmodified
mononucleotides46. Indeed, several reports provide evidence to support BER mechanisms,
such as the requirement of BER-related enzymes and low methylation levels in AID
deficient PGCs47,48. Even if AID is completely eliminated, demethylation of PGCs still
occurs, suggesting the existence of other possible DNA demethylation mechanisms.

1.2 5-HYDROXYMETHYLCYTOSINE AND TET FAMILY PROTEINS
The first discovery of 5hmC was reported in frog and rodent brain DNA in 1971, but
this amazing finding did not draw too much attention49. In 2009, two labs shed light on
the mystery nucleotide in mammalian DNA (Figure 3&4). Kriaucionis and Heintz (2009)
detected an unusual nucleotide when comparing the abundance of 5mC in cerebellar
Purkinje neurons and granule cells38. Subsequent experiments determined the nucleotide
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as 5hmC, but the abundance of 5hmC is quite low with less than 1% of total nucleotides
in cerebellar Purkinje neurons and granule cells38 (Figure 4). In another study, Rao and
colleagues (2009) showed that the Ten Eleven Translocation (TET) family proteins
catalyze the conversion of 5mC to 5hmC (Figure 5), suggesting a novel epigenetic
regulation of 5hmC37. In addition, 5hmC expression level was found to be higher in
mouse embryonic stem cells (mESC) than other cell types. Both Tet1 and 5hmC levels
are downregulated upon the differentiation of mESC, suggesting a potential role of Tet1
and 5hmC in epigenetic reprogramming37. The recurrence of 5hmC has caught the
interest of many towards providing detailed characterization of its biological functions.
Ten Eleven Translocation 1 protects the promoter region of Nanog in an unmethylated
state, which regulates ESC self-renewal and lineage commitment. Once Tet1 is knocked
down, the promoter of Nanog returns to a methylated state and finally contributes to gene
silencing. In contrast, the overexpression of Tet1 triggers the demethylation of
methylated plasmid DNA50.
In various human and mouse cells, 5hmC displays differential profiles, suggesting a
critical balance between 5mC and 5hmC, which may subsequently maintain the cell in its
normal state37,38,51. Except for serving as an intermediate during active DNA
demethylation, 5hmC may have other functions in biological systems. The baseresolution level of 5hmC helps to uncover its biological roles. Several techniques have
been developed to map 5hmC architecture in the genome. These techniques include
cytosine-5-methylenesulfonate

sequencing,

oxidative

bisulfate

sequencing,

hydroxymethyl DNA immunoprecipitation sequencing and Tet2-assisted bisulfite
sequencing52-56 (Figure 6). Studies using these techniques have characterized 5hmC
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profiles in different cells and tissues. For example, 5hmC accounts for 1% of total 5mC
in immune cells, 5-10% of total 5mC in ES cells and 40% of total 5mC in neural
cells37,38,57. Whereas, 5fC and 5ca represent only 0.03% and 0.01% of total 5mC in mouse
ES cells39. Analysis of genome-wide Tet1-dependent 5hmC distribution, has shown that
Tet1 and Tet1-dependent 5hmC are enriched at transcription start sites (TSS) along with
repressive histone modifications58,59. However, other labs have obtained opposite results,
in which 5hmC and histone modifications are enriched at enhancers, promoters and exons
in order to regulate active transcription60-62. These differences are plausible for
independent mechanisms, different techniques and the variation of 5hmC dynamics from
cell to cell during 5hmC signal capture. In addition, 5hmC abundance changes
dynamically during human CD34+ cell and erythroid development such that 5hmC
increases at erythroid-specific transcription factor binding sites and decreases at
repressive genes. Also, rapid DNA demethylation is observed during erythropoiesis63,64.
Therefore, it is reasonable to assert that 5hmC regulates transcription activation or
repression during cell differentiation. The later discovery of TET family proteins has
helped to better understand the importance of 5hmC and 5hmC dynamics in gene
expression and cell-fate decision.
Ten-eleven translocation (TET) family proteins contain two key components: Fe (II)
and 2-oxoglutarate (2-OG) to catalyze oxidation of the methyl group of 5mC to
hydroxymethyl, formyl and carboxyl groups, which generate 5-hydroxymethylcytosine,
5-formylcytosine and 5-carboxylcytosine step-by-step in an enzymatic activity-dependent
manner39,65. Presently, the biological functions of 5hmC, 5fC and 5caC are not wellstudied, but most of recent studies have pointed potential roles to DNA demethylation,
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which regulates gene expression by a series of enzyme catalysis and DNA repair
mechanisms3. All three family members of TET: TET1, TET2 and TET3 are present in
different mammalian tissues57. They participate in diverse biological processes, i.e., gene
transcription, embryonic development and cancer initiation/progression.
The discovery of TET proteins originate from analysis of J-binding-protein 1 (JBP1)
and JBP2 in the parasite Trypanosoma brucei that causes African sleeping sickness66.
Such species contain base J, a modified thymine in which β-D-glucosyl-hydroxymethyl
group is added up to uracil, which enzymatic process is catalyzed by JBP1 and JBP2
which are capable of oxidizing methylthymine to 5-hydroxymethyluracil, and the
intermediate is then further glucosylated by an unknown glucosyltransferase67,68 (Figure
3). The J-binding-proteins belong to Fe(II) and 2-oxoglutarate dependent dioxygenases.
In T. brucei, most of base J resides in silent copies of variant surface glycoproteins that
help parasites evade host immune defense69. When computational screening of JBP
homologues were used to predict nucleic acid modifying dioxygenases, TET family
proteins were identified in eukaryotic cells and bacteriophages (Figure 3). Ten-eleven
translocations are present in all metazoans but not in Caenorhabditis elegans because of a
loss of methylation function70. On the basis of the chemical similarity between thymine
and 5mC and the protein structure of TET, it is possible that TET proteins may oxidize
5mC in mammalian genome.
All three TET proteins contain a Cys-rich domain and a carboxy-terminal catalytic
domain that forms a double-stranded β helix (DSBH). Evolutionary studies indicate that
the ancestor TET gene triplicated to TET1, TET2 and TET371 (Figure 5). Furthermore,
TET2 underwent chromosomal inversion, which resulted in the detachment of CXXC
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domain, thereby encoding a separate gene called IDAX72. Many chromatin-binding
proteins contain CXXC domains. The CXXC domain of IDAX preferentially binds to
unmethylated CpG in CGIs. Strangely, TET1 CXXC domain does not bind DNA
regardless of whether CpG is methylated or not73. On the other hand, TET3 CXXC
domain binds to unmethylated cytosine even if the resulting nucleotide is not a guanine
(supported by X-ray crystallography)74. Ten-eleven translocation 2 no longer has a
CXXC domain, but instead IDAX (Figure 5). The loss of IDAX in ES cells prevents
TET2 from being degraded in a caspase-dependent destruction mechanism during ES
cells differentiation while the depletion of TET2 in human myeloid cell line upregulates
TET2 and 5hmC levels. If CXXC domain of IDAX was mutated, IDAX lost the control
of TET2 and 5hmC suggesting IDAX recruits TET2 to chromatin and TET2 binds to
DNA through a Cys-rich domain72 (Table 1.2).
The C-terminal of TET2 catalytic domain is composed of a Cys-rich domain and
DSBH domain75. The crystallized TET2 catalytic domain made it possible to uncover a
detailed inspection of TET2 DSBH bound to methylated DNA. According to the crystal
structure of TET2, two Zinc fingers stick Cys-rich and DSBH domains together to form a
catalytic domain. The Cys-rich domain stabilizes DNA substrate with proximity to DSBH.
5mC stays in the catalytic cavity in which a methyl group is pointed to Fe(II) for further
oxidation76. The structural features of TET2 catalytic domain helps to better understand
the mechanisms of TET-mediated DNA interaction and oxidation.
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1.3 TET2 GENE IN HEMATOPOIESIS AND HEMATOLOGICAL DISORDERS
All the DNMTs contribute to hematopoiesis16. The deletion of Dnmt1 in
hematopoietic stem cells (HSC) and progenitor cells (HPC) leads to defects in
hematopoiesis at early stages, characterized by an insufficient myeloid cell population
and a decreased myeloid progenitor pool77,78. The loss of Dnmt3a and/or Dnmt3b in
mouse HSC shows a deficiency in HSCs self-renewal, with no lineage commitment of
HSC shift. However, serial transplantation studies have shown that Dnmt3a is required to
maintain HSC differentiation potential79,80. In addition, exome sequencing of patients
with acute monocytic leukemia (AML-M5) indicate that DNMT3A mutations occur in
20.5% of cases81 (Table 1.1). All of these studies demonstrate that DNMT3 are critical
for maintaining normal hematopoiesis.
In addition to identified biological roles in epigenetic reprogramming, stem cell selfrenewal and embryonic development, several studies have reported the genetic alterations
of TET2 in myeloid malignancies, including in myelodysplastic syndrome (MDS),
myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML) and chronic
myelomonocytic leukemia (CMML), while TET1 and TET3 are rarely mutated in
hematological malignancies82. A large number of single/double -copy defects, nonsense
and frameshift mutations of TET2 throughout the gene are commonly found in clinical
patients83 (Figure 7 & 8). The above high genetic alteration frequency of loss-of-function
mutations indicates a critical role for TET2 in the cause and/or progression of leukemia.
And if it is true, at least biological functions of TET2 could be determined by genetic
tools. Previously, Xu and other groups showed that Tet2, a potential tumor suppressor
gene, has multiple biological effects on the development of myeloid malignancies84-87.
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Although the targeting strategies were different, all of the Tet2-/- mice developed similar
phenotypes including an elevated hematopoietic progenitor cell population, and HPC
differentiation skewed toward myelomonocytic lineage.
To fully unearth and characterize the nature of Tet2 in myeloid malignancies, four
research groups generated Tet2 knockout murine models by different strategies. For
example, Li et al (2011) inserted nLacZ/nGFP instead of partial exon 3 of Tet2 gene
since exon 3 is the first and largest coding exon in Tet2 and is also highly mutated in
myeloid malignancies84. Through a specific interbreed crossing, a global knockout mouse
model (Tet2-/-) was obtained (Figure 10). On the other hand, Moran-Crusio and
colleagues (2011) generated a conditional knockout mouse model in hematopoietic
compartment (vav-cre; Tetf/f)87. However, the other two groups’ disruption approaches
were slightly different. Quivoron and colleagues (2011) generated two models, including
a gene-trap targeting intron 9 (Tet2LacZ/LacZ) and a conditional knockout targeting exon 11
(Mx1-cre; Tet2Lox/Lox)86. Both of these two models lost the DSBH domain, which
eliminated dioxygenase activity in vivo. In addition, Ko and colleagues (2011) deleted
Tet2 exon 8-10 globally to fully remove enzymatic activity85. Together, these global or
conditional Tet2 knockout murine models were viable and fertile and their progeny was
in accordance with Mendelian ratio.
Accordingly, detailed phenotypic analyses were performed on these knockout mice.
We have examined hematologic parameters of WT, Tet2+/- and Tet2-/- as early as 2 to 5
months of age84. Notably, increased WBC counts and abnormal numbers of monocytes
and neutrophils were observed in Tet2-/- peripheral blood. Besides the appearance of
significant hepatosplenomegaly in most of the studies, we also found pale footpads in
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Tet2-/- that may indicate anemia and this was consistent with the decrease in erythrocytes
and platelets counts in Tet2-/-84, suggesting a possible occurrence of monocytosis and/or
neutrophilia in Tet2-/- mice. In addition to these mentioned findings in Tet2-/- mice, other
changes include increased bone marrow (BM) cellularity, splenomegaly and
hepatomegaly, as well as increased numbers of colony forming unit granulocyte,
monocyte (CFU-GM) in BM and spleen. A resulting diagnosis of these Tet2-/- mice is
CMML.
The Tet2+/- and Tet2-/- mice died from 3 to 18 month as a result of spontaneous
lethal hematological malignancies. Compared with age-matched WT mice, postmortem
examination of Tet2-/- mice show remarkable splenomegaly and hepatomegaly, which are
8-15 times and 2-5 times larger, respectively (Figure 10). Histologic studies reveal
massive erythroid and/or myeloid infiltration in spleen and liver. Histopathology and
cytospin studies identify specific cell types as myeloblasts, monocytes/macrophages and
neutrophils84.
Flow cytometric analyses of BM and spleen cell from Tet2-/- mice is consistent with
the results from the histologic analyses. Located in the infiltrated BM and spleen are
large numbers of erythroblasts at different stages and various myeloid cell populations.
Also, a large peritoneal mass and a few white nodules in the liver are observed, which
contains Gr-1+CD11b+ cells, suggesting the existence of myeloid sarcoma84.
To determine whether Tet2 alterations contribute to HSC compartment, previous
studies have used a range of cells. These included analyzing BM from 6-7 weeks old
Tet2-/- mice, with the emphasis on lineage-negative (Lin-), ScaI-positive (Sca+), c-kit –
positive (c-kit+) (LSK) and LK cell populations. But even though results showed
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increased numbers of LSK cells, no obvious myeloid malignancies were observed.
Single-cell clonogenic assays were also performed to determine the effect of Tet2
alterations on proliferation and differentiation of LSK cells. Here, the results showed that
Tet2-/- LSK exhibited higher cloning efficiency than Tet2+/- and WT LSK cells along with
CFU-GM in the colonies84. Taken together, it is reasonable to believe that the deletion of
Tet2 stimulated the differentiation and proliferation of HSC/HPC and facilitated the
development of myeloid malignancies.
Genome-wide whole exome sequencing from different groups have revealed that
TET2 is one of the most frequently mutated epigenetic regulators in CMML (~50%)88-90,
AML (~20%)83,91-93 and MDS (~20%)94-96 (Table 1.1). In many patients, deletion of
TET2 on one allele at 4q24 region occurs with mutations of TET2 on a second allele94
suggesting that haploinsufficiency of TET2 may lead to genome instability through DNA
damage/repair pathways. More than 700 TET2 mutations have been identified in about
2000 leukemic patients97. These harmful mutations impair the enzymatic activity of
TET2, which ultimately result in aberrant DNA methylation profiling and decreased
5hmC levels. The majority of TET2 missense mutations are clustered in two highly
conserved regions (AA 1104-1478 and 1845-2002) that are considered as the catalytic
domain of TET2 protein76. The mutations within these regions may influence proteinDNA association, protein-protein interaction or post-translational modifications. The
TET2 mutations have also been found in lymphoma including angioimmunoblastic T-cell
lymphomas (~76%)98 and peripheral T-cell lymphoma not otherwise specified (~38%)
along with Ras homolog gene family, member A (RHOA) mutations99,100.
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Analyses of clonal architecture and mutation frequency of MDS and CMML
indicate that TET2 mutations occur at an early stage of cell differentiation, which leads to
clonal expansion of leukemic stem cells101,102. However, the loss of Tet2 itself in mouse
models is not able to initiate hematological disorders. In addition, most of TET2 alone
mutations have been observed in older individuals with clonal hematopoiesis but without
hematological malignancies103. Therefore, it is possible to propose that there should be
more gene mutations that serve as “driver mutations” which occur during hematological
malignancies initiation and/or progression. Through meta-analysis of mutational sites of
hematological malignant patients, TET2 mutations co-exist with other gene mutations
such as serine/arginine-rich splicing factor 2 (SRSF2), enhancer of zeste 2 polycomb
repressive complex 2 subunit (EZH2) and additional sex combs like transcriptional
regulator 1 (ASXL1) in MDS and CMML102,104,105 (Figure 9). The SRSF2 belongs to
splicing factors that recognize 3’ splice-site and mediate ATP-dependent interactions
between U1/U2 snRNPs and pre-mRNA. Like TET2, SRSF2 is frequently mutated in
myeloid cancers. EZH2 is an H3K27me3 reader and it is the key component of polycomb
repressive complex 2 (PRC2) while ASXL1 differentially recruits methylated H3 to
promoters and it also mediates deubiquitination of H2AK119ub1104,106,107. In AITL
patients, TET2 mutations accompany a recurrent mutation in RHOA (G17V) which is a
small GTPase that regulates cell morphology and migration99. The DNMT3A mutations
also co-exist with TET2 mutations in T-cell lymphomas99. Therefore, TET2 mutations
happen in the early stages of hematopoietic stem/progenitor cells, but the mutation alone
does not lead to malignant transformations. Additional gene mutations must occur, along
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with TET2 mutations for oncogenesis to take place, as in the case of various types of
hematological malignancies (Figure 11).
In addition to the hematological system, TET genes mutations also exist in solid
tumors at quite low frequencies, according to The Cancer Genome Atlas (TCGA)
database. For example, all TET genes mutations are found in colorectal cancer, clear-cell
renal cell carcinoma and metastatic castration-resistant prostate cancer108-110. It is still
unknown if TET mutations contribute to initiation/progression in these solid cancers.
Additional studies will help to clarify the “driver mutations” in TET mutant background
which trigger cell proliferation and survival during oncogenesis. Crossing TET knockout
mice with current cancer-specific mouse models may help increase our understanding of
TET functions.

1.4 TETS AND 5-HYDROXYMETHYLCYTOSINE IN NEUROGENESIS AND
NEURODEVELOPMENT

Neurogenesis produces various types of functional neural cells from neural stem
cells (NSC). Neurogenesis occurs not only at the embryonic stage but also adult stage
throughout the life span of the individual. Such could be considered as an essential neural
activity/mechanism for regulating learning and memory111.
Embryonic neurogenesis in mice usually starts from embryonic day 8 (E8) to E14112.
During E8-E10, neuroepithelial cells undergo transformation in the ventricular zone (VZ)
and subventricular zone (SVZ), thereby allowing the cells to acquire astroglial
properties113. These radial glial cells (RGs) have “stem” features, which trigger the
generation of nascent neurons or intermediate neuron progenitor cells. When RGs initiate
symmetrical mitosis, neurons are generated. However, if RGs go through asymmetrical
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mitosis, other “stem” cells are produced114. Newly synthesized neurons and glial cells
then migrate to the cortex during embryonic development to thicken the neocortex and
build up complicated neural networks111. At the end of embryonic development, RGs
detach from the ventricular zones, and move to the cortical plate and transform into
astrocytes. Some RGs quietly remain in the SVZ and are responsible for adult
neurogenesis113.
Adult neurogenesis occurs in two germinal zones of the brain: the subgranular zone
(SGZ) in dentate gyrus and subventricular zone (SVZ) in lateral ventricles (Figure 12).
Adult neurogenesis is regulated by many cellular activities including neural stem cell
(NSC)/neural progenitor cell (NPC) proliferation and differentiation, fate determination,
maturation and localization of newborn neurons115,116. And because neurogenesis occurs
largely in these two regions, it is reasonable to postulate that neurogenesis may play a
major role in regulating learning and memory. In SGZ, two types of NSC have been
identified, type I and type II cells. Type I cells are radial glia-like cells, which maintain
self-renewal and may differentiate to type II cells, even astrocytes. As well, the
morphology and cellular markers of type I and type II cells are slightly different. Other
than the common Nestin marker, type I cells are glial fibrillary acidic protein positive
(GFAP+) while type II cells are GFAP-. Two cell types constitute the NSC/NPC in SVZ:
type B cells are self-renewal radial glia-like cells that are able to differentiate to type C
cells, and these transient amplifying cells can also transform into neuroblasts at a later
development period115. Neurogenesis generates various types of neural cells with the
same genome but with distinct properties, suggesting a role for epigenetic regulation in
neurogenesis (Figure 13). Significant DNA methylation occurs in neurons and astrocytes.
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Consider GFAP which is a cellular marker for astrocytes. The promoter region of GFAP
is initially hypermethylated, which blocks the differentiation of astrocytes. However, at
specific stages during development, the GFAP promoter becomes hypomethylated and
then initiates the differentiation of astrocytes. Two additional critical neural factors,
brain-derived neurotrophic factor (BDNF) and fibroblast growth factor (FGF), are
regulated by Tet1 protein in terms of the demethylation of BDNF and FGF promoters117.
Studies that have mapped genome-wide 5hmC, have shown that 5hmC distributes
temporally and spatially during neurodevelopment61,118,119. For example, studies have
shown an age-dependent abundance and distribution of 5hmC in the cerebellum and
hippocampus. Interestingly, 5hmC acquisition in these regions is different than what
would be expected. There is no strong correlation between 5hmC acquisition and 5mC
loss in many important neurodevelopment-related genes, therefore one could argue that
5hmC role in gene regulation may be via a mechanism other than by transient oxidation
in the brain118. To better understand the role of 5hmC in the brain, more than 6000
differentially hydroxymethylated regions (DhMRs) at different ages have been identified.
These DhMRs were only found in adult brain, from 6-week-old brain, but not in postnatal
day 7 (P7) cerebellum, indicating long-term modification of 5hmC in the brain118,119.
Although the correlation of 5hmC abundance and gene transcription is still unclear, the
enrichment of 5hmC and loss of 5mC at gene bodies coincide with gene transcription
activation119. In fact, 5hmC regulation of neurogenesis was reported in 2011. Tet1
overexpression in the dentate gyrus (DG) significantly downregulated the methylation
levels of Bdnf and Fgf1b, highlighting the role of 5hmC in neurogenesis117. Several types
of neurodevelopment and neurodegenerative disorders have been found closely
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associated with 5hmC, such as Rett syndrome, Autism spectrum disorder and
Alzheimer’s disease120.
Because of the extensive roles of 5hmC and TETs, several studies have explored
TET proteins functions in neurogenesis117,121. There is evidence that Tet1-/- mice exhibits
robust loss (~45%) of NSCs in the SGZ compared with WT mice and neurospheres from
Tet1-/- show growth defects. Microarray studies have shown that many genes (Galanin,
Ng2 and Ngb) that are down-regulated during NSC proliferation121. In addition, Tet1-/mice show increased hippocampal long-term repression and memory defects121.
Moreover, in Xenopus, Tet3 has been found to regulate early eye development and
neurodevelopment transcriptionally. Deletion of Tet3 decreases neuronal genes in the
eyes74. The role of Tet2 in neurogenesis is still unknown.
My dissertation begins with a review of the molecular basis of DNA methylation
and demethylation with a particular focus on newly identified 5hmC and TET family
proteins, along with their contribution to the pathogenesis of hematological and
neurological disorders. In chapter 2, I discuss the proposed work on uncovering the role
of Tet2 in hematological malignancies. Section 2.3 introduces the methods and
approaches being used in this chapter. I then describe the results and discussions I have
achieved to date in Section 2.4. Later, in Section 2.5, I draw conclusions about what I
have observed. Given the roles of 5hmC and Tet2 in the nervous system, I discuss
specific findings of Tet2 in adult neurogenesis in chapter 3. In Section 3.3, I describe the
materials and methods being used in this chapter. Section 3.4 presents the results
including Tet2 regulation in NPC proliferation and differentiation. Specific conclusions
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are drew in Section 3.5. Finally, chapter 5 summarizes all the observations of the study
presented in chapter 2 and 3, as well as discusses directions for future research.
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Figure 1 DNA methylation and demethylation pathways.
(A) DNMT1 adds methyl group to hemimethylated DNA. DNMT3a/b add methyl group
to non-methylated DNA. (B) Passive demethylation occurs through the absence of
DNMTs. TETs mediate active DNA demethylation through hydroxylation of 5mC to
5hmC, 5fC and 5caC, which can be recognized and removed by base excision repair. (C)
The molecules involved in DNA methylation and demethylation.
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Figure 3 TETs are the homolog of JBPs.
(A) The biogenesis of base J. JBP1/2 oxidize thymidine to produce 5hmU, which can be
further catalyzed to base J by unknown glucosyltransferases. (B) The multiple alignments
of JBP1, JBP2, TET1, TET2 and TET3 are performed using Clustal Omega. These five
proteins are highly conserved in their oxygenase regions.
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Figure 4 Quantification of x in Purkinje cells and granule cells38.
(A) Nucleoside monophosphates separated from genomic DNA in Purkinje and granule
cells. (B) Reference map.
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Figure 5 The protein structures of TET family.
TETs have a DNA-binding CXXC domain at N-terminal and Cys-rich domain, DSBH
domain located at C-terminal. An ancestral TET gene triplicated into three TET family
members. Chromosome inversion occurred and separated TET2 from its CXXC domain,
which generated IDAX.
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Figure 6 Assays for mapping 5mC and 5hmC at single-base resolution.
Traditional bisulfite sequencing separates 5mC from regular cytosine. TET-assisted
bisulfite sequencing separates 5hmC from 5mC.
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Figure 8 Histogram of TET2 mutations.
Data collected from Catalogue of somatic mutations in cancer database.
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Table 1.2 Identified TET2 interactor123. Several protein complexes, microRNA and
small molecule have been shown to interact with TET2.
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Figure 10 Tet2-/- mice develop lethal myeloid malignancies84.
(A) Targeting strategy of Tet2 knockout mouse model. (B) Appearance of Tet2-/- mice
with pale footpads, splenomegaly and hepatomegaly.
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Figure 11 TET2 background mutations cause various hematological malignancies.
TET2 mutations may occur in hematopoietic stem/progenitor cells with aging suggesting
that additional genetic events lead to the initiation/progression of the diseases.
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Figure 12 Adult neurogenesis111.
In subventricular zone, B-cells (Quiescent RGs) are activated and produce C-cells
(transient amplifying cells). C-cells transform to neuroblasts and migrate though rostral
migratory stream to olfactory bulb as interneurons. In the dentate gyrus, type I
progenitors give rise to type II progenitors, which migrate to granule cell layers and
transform to neuroblasts. The neuroblasts then become immature neurons and merge into
neural circuit through synaptic integration.
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Figure 13 Transcriptional epigenetic regulators in adult neurogenesis.
Green columns highlight the positive regulators and red columns indicate the negative
regulators. The left columns are the regulators that impair NSC differentiation and
neurogenesis. The right columns are the regulators that promote NSC differentiation and
aberrant neurogenesis. This figure was modified from (Yao et al. 2014)111.
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CHAPTER
TET2 PROTECTS GENOMIC STABILITY THROUGH INTERACTING WITH MSH6
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2.1 ABSTRACT
Ten-eleven translocation 2 is a member of dioxygenases that catalyze the multi-step
5mC oxidation. Loss-of-function TET2 mutations are frequently associated with
hematological malignancies; however, the underlying mechanism remains unknown.
Here, I show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies.
The mice with T-cell lymphoma/leukemia are characterized with enlargement of spleen,
liver and thymus. The normal architecture of these organs are disrupted by abnormal
lymphoid with cells aberrantly expressing CD4 and CD8. Mice with B-cell
lymphoma/leukemia display enlarged lymph nodes and atypical lymphoid infiltrates are
observed in the small intestines. Cells with B-cell lineage are altered in different tissues,
particularly, B220+/low IgM/low CD43/CD19+ with high forward scatter. To obtain a
more detailed view of the role of Tet2 in hematopoiesis, sublethally irradiated F1 mice
were transferred with Tet2-/- T-cell and B-cell tumor cells. Both T-cell and B-cell
malignancies were transplantable, suggesting the malignant and neoplastic nature of the
infiltrating T- or B- lymphocytes in Tet2-/- mice. To explore genome-wide genetic
alterations and multiple lineage involvement in Tet2-/- mice, additional exome sequencing
of Tet2-/- tumors were performed, which revealed acquisition of numerous mutations,
including genes frequently mutated in human hematological malignancies such as
Neurogenic locus notch homolog protein 1 (NOTCH1) and fms-related tyrosine kinase 3
(FLT3). The mutation frequency in Tet2-/- tumors is significantly greater at loci
containing Tet2-dependent active demethylation. To investigate the underlying
mechanism by which Tet2 loss may result in genomic instability, I found that TET2
associates with MutS homolog 6 (MSH6), a key component of DNA mismatch repair
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(MMR) using both Tet2-tag knock-in ES clones and human TET2 overexpressing cell
line. The association between TET2 and MSH6 was substantiated by immunostaining.
The latter study showed that these two proteins bind closely to each other at S-phase. To
examine if TET2 loss impairs DNA mismatch repair, I depleted TET2 in HeLa cells.
TET2-deficient cells displayed elevated spontaneous mutational frequencies and
increased microsatellite instability, characteristic of MMR-deficient cells. Consistently,
myelodysplastic syndrome patients with TET2 mutations exhibit significantly higher
mutational events than patients without TET2 mutations. Together, these results suggest
that TET2 protects genomic stability through interacting with MSH6, unveiling a novel
means by which TET2 loss leads to diverse hematological malignancies.

2.2 INTRODUCTION
Ten-eleven translocation (TET) family of methylcytosine dioxygenases (Tet1/2/3)
catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC),
which could be further oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC),
resulting in active DNA demethylation39. The dynamic methylation/demethylation cycle
has been shown to occur at a large number of genomic loci across the genome124. Several
studies suggest that 5hmC may also have DNA demethylation-independent functions and
serve as stable epigenetic marks that recruit specific readers, DNA repair proteins and
transcription factors, with limited overlap between these TET proteins119,125. TET2
inactivation through mutations is a common event in myeloid and lymphoid malignancies,
and has been detected also in solid tumors123. Several TET2 binding proteins have been
identified, including O-linked N-acetylglucosamine transferase (OGT), inhibition of the
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Dvl and Axin complex (IDAX) and early B-cell factor 1 (EBF1)72,126,127 (Table 1.2).
Identification of critical novel partners of TET2 and unveiling functional significance of
these interactions may provide valuable insights into the mechanism underlying the
critical roles of TET2 in tumorigenesis of many cancers.
To fully unearth and characterize the nature of Tet2 in myeloid malignancies, four
research groups generated Tet2 knockout murine models by different strategies. For
example, Li et al (2011) inserted nLacZ/nGFP instead of partial exon 3 of Tet2 gene
since exon 3 is the first and largest coding exon in Tet2 and is also highly mutated in
myeloid malignancies84. Through a specific interbreed crossing, a global knockout mouse
model (Tet2-/-) was obtained. We, and others examined hematologic parameters of WT,
Tet2+/- and Tet2-/- as early as 2 to 5 months of age. Notably, increased WBC counts and
abnormal numbers of monocytes and neutrophils were observed in Tet2-/- peripheral
blood. Besides the appearance of significant hepatosplenomegaly in most of the studies,
we also found pale footpads in Tet2-/- that may indicate anemia and this was consistent
with the decrease in erythrocytes and platelets counts in Tet2-/-84, suggesting a possible
occurrence of monocytosis and/or neutrophilia in Tet2-/- mice. In addition to these
mentioned findings in Tet2-/- mice, other changes include increased bone marrow (BM)
cellularity, splenomegaly and hepatomegaly, as well as increased numbers of colony
forming unit granulocyte, monocyte (CFU-GM) in BM and spleen. A resulting phenotype
of these Tet2-/- mice is potentially CMML. Histologic studies reveal massive erythroid
and/or myeloid infiltration in spleen and liver. Histopathology and cytospin studies
identify specific cell types as myeloblasts, monocytes/macrophages and neutrophils84.
Flow cytometric analyses of BM and spleen cells from Tet2-/- mice are consistent with
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the results from histologic analyses. Moreover, a large peritoneal mass and a few white
nodules with Gr-1+CD11b+ cells were observed in the liver, suggesting the existence of
myeloid sarcoma84. Taken together, it is reasonable to believe that the deletion of Tet2
stimulated the differentiation and proliferation of HSC/HPC and facilitated the
development of myeloid malignancies.
Here, my consideration is to uncover the mechanisms of Tet2 and to discover TET2
interactors to better understand Tet2 loss induced tumorigenesis. Specifically, I proposed
to: 1) characterize hematological malignancies in Tet2-/- mice; 2) use whole genome
analyzing tools to examine Tet2-/- genomic landscape; 3) seek TET2 interactors that
facilitate leukemogenesis; and 4) identify Tet2 regulatory network. Tet2-/- mice develop
spontaneous myeloid, T- and B-cell malignancies. Both T-cell and B-cell malignancies
were transplantable, suggesting the malignant and neoplastic nature of the infiltrating Tor B- lymphocytes in Tet2-/- mice. To explore genome-wide genetic alterations and
multiple lineage involvement in Tet2-/- mice, additional exome sequencing of Tet2-/tumors were performed, which revealed acquisition of numerous mutations, including
genes frequently mutated in human hematological malignancies such as Neurogenic locus
notch homolog protein 1 (NOTCH1) and fms-related tyrosine kinase 3 (FLT3). The
mutation frequency in Tet2-/- tumors were significantly greater at loci containing Tet2dependent active demethylation. To investigate the underlying mechanism by which Tet2
loss may result in genomic instability, I found that TET2 associates with MutS homolog
6 (MSH6), a key component of DNA mismatch repair (MMR) using both Tet2-tag
knock-in ES clones and human TET2 overexpressing cell line. To examine if TET2 loss
impairs DNA mismatch repair, I depleted TET2 in HeLa cells. TET2-deficient cells
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displayed elevated spontaneous mutational frequencies and increased microsatellite
instability, characteristics of MMR-deficient cells. Consistently, myelodysplastic
syndrome patients with TET2 mutations have significantly higher mutational events than
patients without TET2 mutations. I therefore proposed that TET2 protects genomic
stability through interacting with MSH6, unveiling a novel means by which TET2 loss
leads to diverse hematological malignancies.

2.3 MATERIALS AND METHODS
2.3.1 Analyses of mice
Peripheral blood (PB) was collected by retro-orbital bleeding of mice and was
smeared for May-Grunwald-Giemsa staining, and/or subjected to an automated blood
count (Hemavet System 950FS). Morphological analysis and cell differential of BM and
spleen samples were performed via cytospins (5x105 cells/sample) followed by MayGrunwald-Giemsa staining. For histopathology analyses, femurs were fixed in
formaldehyde, decalcified, and paraffin embedded.
Spleens, livers, lymph nodes, thymus and intestine were treated similarly except for
the step of decalcification. Sections (4.5 μm) were stained with hematoxylin/eosin (H&E).
Flow cytometric analysis was performed as previously described84. Total PB white blood
cells were obtained after lysis of red blood cells. Single-cell suspensions from BM,
spleen, liver, lymph node, thymus and PB were stained with panels of fluorochromeconjugated antibodies. Briefly, cells were divided into 40μl aliquots containing 2% FBS
in PBS in 96-well plates. One microliter of antibodies was added into each well and
incubated for 45min at 4°C. Then, the stained cells were re-suspended in 150μl 2% FBS
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in PBS and processed for flow cytometric analysis. Dead cells were excluded by DAPI
staining. The analyses were performed using a BD FACS CantoII or LSRII flow
cytometer. All data were analyzed by FlowJo7.6 software.

2.3.2 Tumor transfer assay
Tumor transfer experiments were performed to evaluate the malignant nature of the
abnormally infiltrated T- or B-lymphocytes in the moribund/deceased Tet2-/- mice.
Briefly, 1x106 spleen cells from primary Tet2-/- or WT mice were transplanted into sublethally irradiated (600 cGy) F1 recipient mice (CD45.1/CD45.2, n=5) through tail veins.
Recipient mice were sacrificed when they became moribund or 6 months after injection.
Donor cell chimerism in the PB, spleen and BM were examined at the end of the
observation period. The mice were also phenotypically analyzed to determine their
hematological phenotype and development of T- or B-cell malignancies. None of the
recipients receiving WT spleen cells developed pathology or gross evidence of disease
within 6 months of transplantation. By contrast, all of the animals receiving spleen cells
from Tet2-/- mice with T- or B-cell leukemia/lymphoma developed diseases with similar
characteristics as those observed in their respective primary donor animals including
elevated WBC counts, lymphocytosis, splenomegaly, enlarged lymph nodes and death.

2.3.3 Generation of FLAG-V5 Tag knock-in ES cells
The targeting vector contained a neomycin (Neo) cassette flanked by two FRT sites,
followed by a 0.5 kb genomic fragment upstream of the Tet2 start codon and an
ATG/3xFlag/V5 sequence. A 2.2 kb 5′ and a 4.8 kb 3′ arm genomic fragments were
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subcloned into the vector for gene targeting. All the fragments were amplified using
KOD Xtreme™ Hot Start DNA Polymerase and ES cell genomic DNA as template.
KOD Xtreme standard reaction:
2X Xtreme Buffer

25 μl

dNTPs (2mM)

10 μl

PCR grade water

10 μl

Primer mix

3 μl

Template DNA

1 μl

KOD Xtreme Polymerase

1 μl

Total volume

50 μl

The three-step cycling was used to amplify the targets: 94°C for 2min, 98°C for 10s,
60°C for 30s and 68°C for 5min. Steps 2-4 were performed for 35 cycles. The targeting
vector was linearized by EcoRI or ScaI and electroporated into 129/sv mouse ES cells
and screened by southern blot. I then examined the levels of WT- and Tagged-Tet2
transcripts in the Tet2:Tag ES cells by allele specific qPCR (ß-actin as internal calibrator).
Using Tet2 primers for both WT-Tet2 and Tagged-Tet2, the expression of WT-Tet2 plus
Tagged-Tet2 mRNA in Tet2:Tag ES cells was comparable to that in the WT ES cells.
While, using the Tagged-Tet2 specific primers, the Tagged-Tet2 mRNA expression was
not detected in control ES cells, suggesting the primers are Tagged-Tet2 mRNA specific.
These data suggest that Tagged-Tet2 mRNA expression was comparable to WT-Tet2
mRNA expression in the Tet2:Tag ES cells.
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2.3.4 Purification of TET2-associated proteins
To search for binding partners of Tet2, I collected 30 plates (10cm) of Tet2:Tag ES
cells. Briefly, cells were washed with PBS and scraped off from the plates. Then, cells
were fully re-suspended in Buffer A (10mM HEPES pH7.6, 420nM NaCl, 1.5mM MgCl2,
0.2nM EDTA and 25% Glycerol) in order to separate cytoplasmic protein. Next, the
remaining suspension was incubated with Buffer C (20mM HEPES pH7.6, 420nM NaCl,
1.5mM MgCl2, 0.2nM EDTA and 25% Glycerol) to obtain nuclear proteins. The nuclear
extracts were incubated with 0.2 ml anti-Flag M2 beads at 4°C for at least 4h. The beads
were washed and associated proteins were eluted twice with 200ng/μl 3xFlag peptide
(Sigma). The eluted proteins were analyzed by 10% SDS–PAGE and gel slices were
subjected to trypsin digestion followed by liquid chromatography and tandem mass
spectrometry (LC-MS/MS) as described previously128. WT ES Cells were used as
purification control.

2.3.5 Constructs
WT TET2 was cloned into pOZ-FH-N vector. A mammalian codon optimized
human TET2 cDNA was cloned into pcDNA3.1 vector. TET2-N (amino acid 1-942),
TET2-M (amino acid 943-1322) and TET2-C (amino acid 1323-2002) were cloned into
pcDNA3.1 vector. Briefly, the human TET2 fragments were amplified by PCR and the
products were sub-cloned to pCR-Blunt II-TOPO for validating sequences.
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Fresh PCR products

3 μl

Salt solution

1 μl

Water

1 μl

pCR-Blunt II-TOPO

1 μl

Total volume

6 μl

The reaction was mixed gently and incubated for 5 min at room temperature. Normally, 1
μl mixture was pipetted directly into one vial of competent cells. The vial was incubated
on ice for 30min. Then, the vial was incubated in 42°C for 30s and on ice for 2min. Prewarmed S.O.C. medium was added to each vial and the vial was incubated at 37°C for 1
hour at 225rpm. About 200μl mixture was spread on the LB agar plates with kanamycin
for colony selection. The sequence confirmed clones were cloned into pcDNA3.1 vector
using NheI and XhoI. Each of these vectors contained Flag-tag and nuclear localization
signal at their N-terminal.

2.3.6 RNA interference
shRNA sequences targeting mouse Tet2 (5′-GCTTACAGAATGGAGGGATAA-3′
or

5′-CGGGTTCATATTTGAATCCTT-3′)

were

inserted

into

the

pLKO.puro.IRES.mCherry vector. Generation of lentivirus was carried out as previously
described.

shRNA

sequences

targeting

human

TET2

(CCGGCCTTATAGTCAGACCATGAAACTCGAGTTTCATGGTCTGACTATAAGG
TTTTTTG)

and

human

MSH6

(CCGGGCCAGAAGAATACGAGTTGAACTCGAGTTCAACTCGTATTCTTCTGGC
TTTTTG) were cloned into pLKO.1-puro vector.
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The tissue culture 6-well plates were treated with 0.01% poly-L-lysine for 5min at RT.
HEK293T cells (1x106) were seeded in each well for 24h using Dulbecco's Modified
Eagle's Medium with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin.
When cells confluence reached 90%, transfection mixture was prepared. 3.75μl
Lipofectamine® 3000 was diluted by 125μl Opti-MEM® Medium. Next, 500ng pLKO
construct, 50ng pCMV-VSVG and 450ng psPAX2 were mixed with 125μl Opti-MEM®
Medium and 5μl P3000™ Reagent. Diluted DNA was added to diluted Lipofectamine®
3000 reagent at RT for 5min. The DNA-lipid complex was dropped to cells. The virus
containing supernatant was collected after 24 and 48h for instant lentivirus titer test using
Lenti-X™ GoStix™. 1x106 HeLa or NIH3T3 cells were re-suspended in 500μl lentivirus
supernatant and transferred to 24-well plates. Polybrene (8μg/ml) was added to each well
and the plate was centrifuged at 2000rpm for 90min at 37°C. Another 500μl complete
medium was added to each well for 48h. The viral-infected cells were selected by
puromycin (2μg/ml) for 72 h and then used for phenotypic and/or functional analysis.

2.3.7 Real-time PCR
Total RNA was isolated and put on ice. The reverse transcription reaction included:
6μl 7xgDNA wipeout buffer, 3μg RNA template and 33μl RNase-free water. The mixture
was incubated at 42°C for 2min and placed immediately on ice. Additional 3μl
quantiscript reverse transcriptase, 12μl 5xQuantiscript RT buffer, 3μl RT primer mix
were added and the tube was incubated at 42°C for 15min and 95°C for 3min. Firststrand cDNA was synthesized. Real time PCR was performed using Fast SYBR Green
master mix. Briefly, each reaction contained 10μl Fast SYBR® Green Master Mix, 2μl
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primer mix and 2μl cDNA template. The plate was applied to Applied Biosystems 7500
fast real-time PCR system following the program: 95°C for 20s, 95°C for 3s and 60°C for
30s, 40 cycles. The PCR amplifications were performed in triplicate for each gene of
interest along with parallel measurements of Gapdh or β-Actin cDNA(an internal control).
To confirm specific amplification of the desired PCR product, melting curves were
analyzed and PCR products were separated on a 3% agarose gel. The data was analyzed
by 7500 Fast SDS v1.5.1.

2.3.8 Western blot and co-immunoprecipitation assays
Cells or tissues were disrupted in either whole cell lysis buffer (50mM Tris, pH7.4,
250mM NaCl, 5mM EDTA, 50mM NaF, 1mM Na3VO4, 1%NP40 and complete
protease inhibitor cocktail) or nuclear extraction buffer. Briefly, cells were washed twice
in ice-cold PBS. For each 10-cm dish, 0.5ml ice-cold cell lysis buffer was added to each
cell culture dish, and incubated on ice for 30min. The cells were scraped off the dish and
transferred to 1.5ml microcentrifuge tubes. The tubes were microcentrifuged for 10min at
4°C, 13,000 x rpm. The supernatant of cell lysate was saved for immunoprecipitation or
SDS-PAGE.
Supernatants or nuclear extracts were incubated with 30μl protein A/G PLUSAgarose (Santa Cruz Biotechnology) and incubated with rotation at 4°C for 1 hour.
The tube was microcentrifuged for 10min at 4°C to preclear the cell lysate. Primary
antibodies FLAG, TET2, MSH6 and so on were added into 400μl cell lysate, and
incubated with gentle rotation overnight at 4°C. Next day, 30μl protein A/G PLUSAgarose was added to the cell lysate for an additional 3 hours at 4°C. Precipitates were
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washed five times with cell lysis buffer, and the pellet was re-suspended with 30μl
2XSDS sample buffer. The samples were heated at 95°C for 6min and centrifuged at
13,000 x rpm for 5min. The samples were loaded on SDS-PAGE (4%-15%). The gel was
then electro-transferred to PVDF membrane (80V, 120 min). After transfer, the
membrane was washed with 25ml TBST for 5min and 25ml blocking buffer (5% non-fat
milk in TBST) for 1hour at room temperature. Later, the membrane was incubated in
10ml primary antibody dilution buffer (1:1,000) with gentle rocking overnight at 4°C.
Next day, the membrane was washed 3 times for 5 min each with TBST. The membrane
was incubated with horseradish peroxidase (HRP)-linked secondary antibody dilution
buffer (1:10,000) for 1 hour at room temperature. The membrane was the washed 3 times
for 5 min each with TBST, and ECL substrate was added onto the membrane in the dark
and exposed to x-ray film. Proper exposure time was performed to detect signals.

2.3.9 Exome sequencing and mutational confirmation
Initial whole-exome sequencing was carried out in order to identify candidate
mutations in the exome of genes. The genomic DNA was captured with the NimbleGen
mouse exome array according to the manufacturer’s protocol and 100bp paired-ended
sequencing was performed on the Illumina HiSeq 2000. Raw sequencing reads were
mapped to the whole mouse genome (mm10) using the PEmapper
(http://pemapper.sourceforge.net/) with the default settings, and variant bases were
annotated with SeqAnt (http://seqant.genetics.emory.edu/).
For the samples subjected to mutational detection, genomic DNA was amplified in
selected exons by PCR, and sequenced by means of Sanger sequencing. The location and
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types of mutations were then determined by sequencing data.
The exome-Seq was performed and analyzed by Thomas Wingo from Emory
University, Georgia.

2.3.10 DNA Mismatch repair assays
In vitro MMR assays were performed essentially as described with some
modifications. A circular DNA substrate containing a G-T mismatch and a nick 3’ to the
mismatch was incubated with 75 μg or 150 μg of whole cell extracts at 37°C for 15 min.
DNA samples were digested with Nsil (repair scoring enzyme), followed by
polyacrylamide gel electrophoresis and Southern blot analysis to identify repaired and
unprepared molecules.

2.3.11 Microsatellite instability and HPRT mutability analyses
The MSI and HPRT mutability analyses were performed as described previously129.
For the detection of MSI in mouse bone marrow cells, 5 microsatellite markers (A33,
Bat26, Bat66, D6Mit59, and D1Mit62 loci) were used. The D1Mit62 CA repeat loci were
used as negative control as these loci are stable. For the human cell lines tested for MSI,
independent single cell colonies were isolated in 96-well microtiter plates, and genomic
DNA was isolated. Four microsatellite markers (BAT25, BAT26, D2S123, and D5S346)
were used for MSI analysis. The HPRT mutation assay was conducted as described
previously129. Cells (5x105) were seeded in triplicate 10 cm Petri dishes for 12 hr and fed
with complete medium containing 5 μM freshly prepared 6-thioguanine (6-TG). The
plating efficiency was determined by culturing 500 cells similarly in the absence of 6-TG.
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After 10 days of culturing, cell colonies were visualized by staining with 0.05% crystal
violet. The mutation frequency was determined by dividing the number of 6-TG-resistant
colonies by the total number of cells plated after being corrected for the colony-forming
ability.

2.3.12 Confocal Microscopy and immunofluorescence analysis
Immunofluorescence analysis was performed as described below. Coverslips were
treated by 0.01% polylysine for 5min at room temperature. The remaining polylysine
solution was aspirated and the coverslips air-dried for 10min. 105 cells were seeded into
6-well plates with coated coverslips overnight. Next day, the medium was aspirated and
the monolayer was washed 2X with PBS. Then the cells were fixed in fresh 2.5% PFA at
37°C for 10min. The coverslips were rinsed 2X with PBS and washed 1X with PBS in
the dark for 10min. The cells were permeabilized and blocked with SS-PBS buffer (10%
normal goat serum and 0.3% Triton™ X-100) at room temperature (RT) for 5min. After
SS-PBS buffer was removed, 10μl primary antibody was added directly onto the
coverslips for 60min. The well was rinsed 2X with PBS and 1X with SS-PBS in the dark
for 10min. 10μl secondary antibody was added onto the coverslips directly after SS-PBS
was removed from the well completely. The plate was left at RT in the dark for 30min.
The coverslips were rinsed 2X with PBS, 2X with PBS+0.3% Triton™ X-100 and 2X
with PBS. After wicking the majority of buffer from the coverslips, the coverslips were
mounted using Prolong Gold anti-fade reagent. The coverslips were set overnight in the
dark and used for imaging next day. Fluorescence images were obtained using Olympus
FV1000 MPE or Leica SP8 MP. The images were analyzed by ImageJ 1.48 software.
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2.3.13 Bisulfite-Seq and TAB-Seq
Genomic DNAs (500ng) from WT and Tet2-/- mice LK cells were mixed with 130μl
CT conversion reagent. The tubes were placed in a thermal cycler under the following
program: 98°C, 10min; 64°C, 150min; 4°C for up to 20 hours. The products were
transferred to spin columns with 600μl binding buffer. The columns with collection tubes
were centrifuged at 10,000xg for 30s. After washing the column twice with washing
buffer, the columns were filled with elution buffer. The eluted DNA was ready for PCR
or further analyses.
Genomic DNAs from WT and Tet2-/- mice LK cells were sheared to average 400bp.
The β-glucosyltransferase reaction was prepared as follows: 4μg sheared gDNA, 0.4μl
10mM UDP-Glucose, 2μl 10xβGT protection buffer, 0.5μl T4-βGT and Milli-Q water to
20μl. The reaction was performed at 37°C for 1h. The products were then purified using a
QIAquick PCR Purification Kit. Next, 500ng gDNA from the last step was incubated
with TET1 protein and Tet2 oxidation reagent 1&2. The reaction was carried-out at 37°C
for 1h. 1μl Proteinase K was added to the reaction and incubated at 50°C for 1h. The
product was purified by Micro-Bio-Spin Columns and then with QIAquick PCR
Purification Kit. The target sites were amplified by PfuTurbo Cx DNA polymerase
following the manufacture’s instructions. Generally, 50μl PCR included 5μl
10xPfuTurboCx reaction buffer, 1μl 10mM dNTP mix, 2μl 5mC control primers, 4μl
Bisulfite treated DNA, 1μl PfuTurboCx DNA polymerase and Milli-Q water to 50μl. The
verified PCR products were used for either individual clone sequencing or Genome-wide
Sequencing analysis.
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2.3.14 Statistical analysis
To determine differences between experimental groups, I used the Student’s t-test or
analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests as
appropriate. P values < 0.05 were considered significant. For SNV count data, chi-square
tests were used as implemented in R (http://cran.r-project.org/).

2.4 RESULTS AND DISCUSSION
2.4.1 Tet2-/- mice develop lymphoid malignancies.
The TET2 gene is frequently mutated in human hematopoietic malignancies. Most
of these homozygous and heterozygous mutations lead to truncation of TET2 protein and
subsequently decreased TET2 enzymatic activity. Several groups generated Tet2
knockout mouse models to determine the role of TET2 in hematopoiesis and
hematopoietic diseases84-87. Similar phenotypes were observed from these groups that
Tet2-/- mice developed a wide spectrum of myeloid malignancies and the loss of Tet2 was
sufficient to promote myeloid transformation. It is still unknown if the deletion of Tet2 is
able to cause lymphoid transformation, as previously reported, that TET2 mutations also
exist in patients with lymphoid malignancies100. A long-term investigation was performed
to determine if the loss of Tet2 is sufficient to cause lymphoid transformation. I
conducted a 2-year study on a cohort of Tet2-/- and 67 wild-type (WT) mice. All the Tet2/-

mice were born with expected Mendelian ratios, were viable, fertile with normal organ

development, suggesting Tet1 and Tet3 may have extra roles in embryonic development.
No expression level changes in Tet1 and Tet3 were seen in hematopoietic cells after Tet2
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deletion, which eliminates the presumption of enzymatic compensation in TET family
and endows a unique role for Tet2 in hematopoiesis.
Next, I analyzed details of the incidence, latency, and pathological features of
hematological neoplasms that occur in Tet2-/- mice and Tet2+/+ littermates. Strikingly, all
of the 198 Tet2-/- animals developed spontaneous lethal hematological malignancies with
a latency ranging from 3 to 18 months, while no progressive leukocytosis was
characterized in the hematopoietic organs of WT animals (Figure 14).
Analyses of these Tet2-deficient mice strengthened the finding that a majority of
(>90%) these Tet2-/- mice developed predominantly myeloid malignancies that include
CMML-like disease, MDS and MPN with significant hematological phenotypes of
leukocytosis (accompanied by neutrophilia and/or monocytosis), hepatosplenomegaly
and marked expansion of well-differentiated myeloid cells or erythroid precursors in the
bone marrow (BM), spleen, and liver that compromised the normal architecture of these
organs. Interestingly, Tet2 loss also affects lymphoid-lineage development. The rest of
Tet2-/- mice developed T-cell (7 of 198, 3.5%) or B-cell (9 of 198, 4.5%)
lymphoma/leukemia (Figure 14). With age, these mice showed lymphocytosis consisting
of atypical lymphocytes, lymphadenopathy, hepatosplenomegaly, and/or enlarged thymus
(in most cases of T-cell malignancies).
The mice with T-cell lymphoma/leukemia were characterized with lymphoid
infiltration in BM, thymus, spleen and liver (Table 2.1). Histopathological analysis of
moribund mice indicated complete effacement of the normal architecture of these organs
with lymphoid elements. The morphology of atypical lymphocytes was observed (Figure
14). They were medium sized, immature appealing with irregular nuclei and small to
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moderate amount of cytoplasm. The spleen specimen exhibited a diffuse infiltrate within
both red and white pulp. The predominant hepatic perivascular and sinusoidal infiltrates
were also observed after histological examinations. Flow cytometric analysis confirmed a
predominant proportion of T-lymphocytes expressing CD3 and aberrantly co-expressing
CD4 and/or CD8 in BM, spleen and thymus (Figure 15).
Atypical lymphoid infiltrate was also identified in the small intestines with
lymphoepithelial lesions and lymphoid nodules in Tet2-/- mice diagnosed as B-cell
lymphoma/leukemia (Table 2.2). These atypical lymphocytes were medium sized with
irregular nuclei, condensed chromatin and small amount of cytoplasm. Nodular lymphoid
infiltrate disrupted the normal architecture of the spleen, especially in the white pulp.
Requisite perivascular and sinusoidal infiltration occurred in the liver. The B-cell lineage
was also altered in different tissues, particularly, B220+/lowIgM+/lowCD43+CD19+ with
high forward scatter (FSC) (Figure 16).
To obtain a more detailed view of the role of Tet2 in hematopoiesis, I transferred
Tet2-/- spleen cells from Tet2-/- mice with T- and B-cell malignancies to sub-lethally
irradiated WT mice. Two weeks later, transplanted mice were analyzed. Both T- and Bcell malignancies were transplantable, suggesting the malignant and neoplastic nature of
the infiltrating T- or B-lymphocytes in these Tet2-/- mice (Figure 17).
Taken together, these results show that besides myeloid malignancies, Tet2-/- mice
also develop lethal lymphoid malignancies involving both T- and B-cell lineages. These
finding are consistent with the clinical observations that loss of function mutations of
TET2 are frequently associated with T- and B-cell malignancies. The kinetics of disease
onset suggests that additional genetic lesion events may occur along with Tet2 ablation to
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cause distinct types of hematological malignancies, either in myeloid or lymphoid lineage.
It is reasonable to speculate that the deletion of Tet2 may contribute to locus specific
hypermethylation. Aberrant methylation at specific myeloid, T-cell and B-cell promoters
should correlate with transcription alterations and later disease development.

2.4.2 Acquisition of mutations in Tet2-/- tumors and increased mutational frequency
in loci marked by Tet2-dependent 5hmC
To explore if the loss of Tet2 leads to genome-wide genetic alterations, I performed
comparative genomic hybridization array (aCGH) and whole-exome sequencing using
tumor and/or non-tumor cell genomic DNA from Tet2-/- mice with myeloid-, T- or B-cell
malignancies. In the myeloid tumor sample, CGH analysis detected a gain of 16q (Figure
18). Both myeloid- and T-cell malignant genomes showed sub-chromosomal copy
number alterations. While no significant alterations were seen from B-cell malignant
genome (Figure 18).
The newer and current massive parallel sequencing techniques make it feasible to
characterize somatic mutations in cancers. The exome (coding regions) sequencing
allows us to identify driver mutations in cancer genome. To gain new insight into Tet2
loss induced leukemogenesis and relevant molecular basis underlying the clinical finding
of multiple lineage involvement, I performed whole exome sequencing and subsequent
Sanger sequencing to identify somatic mutations in Tet2-/- myeloid-, T- and B-cell tumors.
I captured and sequenced the exomes from paired samples of Tet2 loss induced tumors.
After normalization (remove SNVs from WT and Tet2-/- non tumor samples), I identified
potential somatic mutations including 3,309 single-nucleotide variations (SNVs) and 211
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small insertions or deletions (indels). I analyzed the alterations affecting protein-coding
sequence, and 1,480 non-synonymous replacement sites and 1,829 silent sites per tumor
type were found, which influence the integrity of open reading frame. Of the Tet2-/tumors from each cell origin, I found somatic mutations in 190 genes with recurrent
SNVs that appeared to originate in the different tumors including Notch1, Ebf1, Flt3, Nf1,
Rhoa and Ikzf3 (Figure 19). Integration of the above data, together with literature
searching for these genes which have been frequently found in human hematological
malignancies, led to the validation of exome sequencing results. I amplified the
corresponding regions from original tumor samples and applied the PCR products for
Sanger sequencing.
Non-synonymous mutations of Notch1 were identified in all 3 cases of Tet2-/- T-cell
tumors. As a critical transcription factor regulating innate and adaptive immunity,
NOTCH1 can direct hematopoietic stem cell differentiation toward T-cells. In addition,
NOTCH1 is frequently altered in hematopoietic and solid tumors. Intriguingly, NOTCH1
genetic mutations may lead to either ligand-independent activation or delayed turnover of
NOTCH1 protein, depending on the context and mutation induced conformation
changes130.
In the hematological system, NOTCH1 mutations have been detected not only in
~55% of human T-cell acute lymphoblastic leukemia (T-ALL) but also in a high fraction
of murine precursor-T lymphoma/leukemia in which NOTCH1 is a well-characterized
oncogene130. Previous studies have shown that the HD (heterodimerization) and PEST
(proline-glutamic acid-serine-threonine rich) domains of NOTCH1 are mutation hotspots
in T-ALL131. Indeed, the Notch1 mutations identified by exome sequencing of Tet2-/- T-
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cell tumors are all within these hotspots (p.Leu1668Pro, p.Arg1673Pro) and the Notch1
mutations in these hotspots were also found in 3 additional cases of Tet2-/- T-cell tumors
(p.Thr2346---, p.Ala1639Thr, p.His1598*) (Figure 20), providing novel insight into the
T-cell leukemogenesis caused by the loss of Tet2.
Together, Tet2 loss-induced tumors are characterized by the acquisition of SNVs
and small indel, but not large chromosomal deletions/amplifications, suggesting that the
loss of Tet2 may create a genomic instability state in cells, where gene mutations accrue
much more readily than normal. Indeed, hypermethylation states have been shown to be a
potential mutagen in tumor cells.
Given the role of TET proteins in the oxidation process of 5mC, I next examined the
effect of the loss of Tet2 on genome-wide 5hmC modification. I mapped the genomic
distribution of 5hmC in WT and Tet2-/- Lin-c-Kit+ (LK) BM cells using selective chemical
labeling and affinity enrichment procedures (Figure 21). The deletion of Tet2 leads to a
significant decrease of 5hmC at gene bodies, which is consistent with previous
observations in mouse ES cells with a reduced expression of Tet2. The effects of Tet2
loss engendered a striking dependence on intermediately-expressed, but not highlyexpressed genes in LK cells (Figure 22). The majority of Tet2-dependent 5hmC
modifications in LK cells are located within the genes. Genome-wide 5hmC profiling of
WT and Tet2-/- LK cells identified the shared loci.
The shared loci represent the ones with 5mC oxidation catalyzed by other TET
proteins, such as TET1, but not Tet2 (Tet2-independent sites). Both gain and loss of
5hmC loci in the absence of Tet2 may represent loci with Tet2-dependent 5mC oxidation
and might reflect distinct role(s) for Tet2 in the 5mC oxidation process. The loci with the
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loss of 5hmC in the absence of Tet2 are the ones that are converted from 5mC to 5hmC
by Tet2 (Tet2-dependent 5mC conversion to 5hmC), while the loci with the gain of
5hmC more likely represent the regions with further 5mC oxidation (from 5hmC to
5fC/5caC) mediated by Tet2 (Tet2-dependent active DNA demethylation) (Figure 23). I
then explored the overlap between the sites with SNVs/indel in Tet2-/- tumors and the
three different genomic loci. Using a chi-square test to examine the correlation between
mutation sites and three different genomic loci, I observed a significantly greater
frequency of SNVs/indel within the loci that require Tet2 for active demethylation, as
compared to that of Tet2-independent sites and the loci that require Tet2 for the
conversion of 5mC to 5hmC alone. Similar increases were observed with either overall
mutations or C to T (or G to A) mutations (Figure 23 & 24). Thus the genetic loci marked
by Tet2-mediated active demethylation are likely accessible by Tet2, which could in turn
play a role in the maintenance of genomic stability.
I observed a decrease in 5hmC abundance at mutation sites as these regions close to
CpG sites, which further indicates that Tet2 loss induced genetic mutations correlate with
Tet2-mediated DNA demethylation. To determine the dynamics of 5hmC alterations at
mutation sites, I used single-base resolution Bisulfite-Seq and TAB-Seq to examine the
changes of cytosine modification between WT and Tet2-/- young mice LK cells, in which
I assumed that these mutation sites stay in origin. From representing gene analysis
(Akap12), I found the “C” was hypermethylated in Tet2-/- cells but no expected 5hmC
changes were observed (Figure 25), suggesting that the C base confers an essential
function to maintain genome integrity because 5mC is considered as a mutagen in the
genome and the accumulation of 5mC may alter its active enzymatic deamination.
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Although I was not able to detect 5hmC changes, I cannot exclude the dynamics of 5hmC
because of 1) 5hmC overlapping region controlled by TETs; 2) 5hmC further oxidized to
5fC or 5caC; 3) Technique limitations.

2.4.3 TET2 interacts with MSH6
To investigate the mechanisms by which Tet2 loss may result in genomic instability,
I sought the functional Tet2-binding partners. I generated knock-in ES clones in which
tandem (Flag and V5) tags were inserted after the Tet2 start codon within exon 3 through
homologous recombination (Figure 26). The knock-in allele allows the expression of both
Flag-tagged Tet2 and WT Tet2 at roughly 1:1 ratio in the Tet2:Tag ES cells.
I characterized endogenous TET2-interacting proteins by mass spectrometry, and
identified a list of TET2-interacting proteins including the known TET2-interacting
protein OGT, and unknown associates MSH6 (Table 2.3). These results are intriguing as
MSH6 is specifically involved in the DNA mismatch repair (MMR) of base-base
mismatches and small insertion/deletion mispairs generated during DNA replication129,
consistent with the types of genetic alterations identified in the Tet2-/- tumors. To confirm
interaction between TET2 and MSH6, I performed co-immunoprecipitation assays using
both Tet2:Tag ES cells and Flag-TET2 overexpressing HEK293 cells (Figure 27 & 28).
TET2 was also captured in the MSH6 precipitates from mouse BM cells, confirming the
endogenous TET2-MSH6 interaction in primary hematopoietic cells. To map the
interacting regions between TET2 and MSH6, I generated a series of constructs including
Flag-TET2 fragments and Myc-MSH6 fragments. Human TET2 gene was fragmented to
four parts: hTET2-N (AA 1-942), hTET2-M (AA 916-1921) and hTET2-C (AA 1323-
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2002, DSBH) (Figure 29). On the basis of the secondary structure of human MSH6, the
MSH6 gene was dissected to five fragments that are MSH6-PWWP (AA 1-200), MSH6MutSNter (AA 183-537), MSH6-MutSConnector (AA 525-735), MSH6-MutSCore (AA
700-1102) and MSH6-MutSCter (AA 1075-1360). TET2-N terminal showed interaction
with full-length MSH6. To examine if MSH6 directly interacts with TET2 protein, I also
co-expressed GST-MSH6 and TET2-N. These two recombinant proteins were co-purified
in vitro, suggesting the direct binding between TET2 and MSH6 in vivo and in vitro.
Moreover, the co-localization of the two proteins was examined using HeLa cells and
immunofluorescence staining. Consistent with previous reports129, MSH6 formed distinct
foci in the chromatin of HeLa cells, and the localization of MSH6 and TET2 largely
overlapped in these foci (Figure 30). These data collectively demonstrate that TET2
interacts with MSH6 in vivo.

2.4.4 TET2 loss causes a mutator phenotype in cells
Mismatch repair (MMR) of DNA corrects base-base and small insertion/deletion
generated during DNA replication. Since MMR reduces the DNA replication errors,
defective MMR increases the spontaneous mutation rate, which results in the “mutator
phenotype”129. In mammalian cells, these mispair errors are recognized by human
heterodimer proteins hMutSα and hMutSβ. MSH2 and MSH6 are major components of
hMutSα and they form a heterodimer to repair the mispairs. Previous studies indicate that
the alteration of MSH2 and MSH6 expression leads to susceptibility to certain types of
cancer, especially hereditary non-polyposis colorectal cancer (HNPCC)132. The MMR
defects cause the instability of high frequency of insertion/deletion in microsatellites at
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the cellular level. Microsatellite instability (MSI) is a hallmark characteristic in hereditary
nonpolyposis colorectal cancer (HNPCC), which is associated with mutations in the
MMR pathway genes including MLH1, MSH2 and MSH6129. In addition to colorectal
cancer, MSI phenomenon is also observed in certain types of leukemia such as secondary
AML and MDS133.
The above TET2 and MSH6 interaction data prompted the following question. Does
TET2 loss impair MMR and subsequently cause the mutator phenotype? To answer these
questions, I first examined the in vitro MMR activity and MSH6 expression in the
nuclear extract of WT and Tet2-/- total BM cells. A functional in vitro MMR assay was
performed. Surprisingly, both WT and Tet2-/- BM cell extracts restored MMR efficiently
(Figure 32), suggesting TET2 is not a critical factor for MMR in vitro and Tet2 loss does
not alter the expression or function of MSH6 in vitro.
However, if the MSH6-TET2 interaction recruits hMutSα to chromatin, I cannot
exclude the possibility that MSH6-TET2 interaction is required for MMR in vivo. If this
is true, TET2 deficient cells should have impaired MMR and displayed an increased
mutation frequency. To determine MSH6 chromatin localization, I depleted TET2 by
shRNAs in HeLa cells (Figure 33), which is a MMR-proficient cell line. I used double
thymidine block to synchronize control of HeLa (scramble shRNAs) and TET2KD HeLa
cells in G1, S and G2/M phase. Then, endogenous MSH6 expression levels and
chromatin localization were determined by immunofluorescence (Figure 31). Decreased
MSH6 foci were observed in TET2KD HeLa cells compared to control HeLa cells
(Figure 36), suggesting that MSH6 chromatin localization is facilitated by TET2. Around
10% of MSH6 foci co-localized with TET2 in WT HeLa cells indicating that not all
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TET2 recruit MSH6. Like a previous report129, decreased MSH6 foci is also seen in
G2/M phase, but not because of altered MSH6 expression.
Control and TET2-depleted HeLa cells were then tested for MSI at four
microsatellite loci as described previously129. No MSI was detected in control HeLa cells,
whereas 9-18% sub-clones (n=11) from TET2-depleted HeLa cells showed new
microsatellite species at these loci (Figure 38). As a positive control, MSI was also
analyzed in MSH6-deficient DLD-1 cells, which exhibited new repeat species in 27-36%
sub-clones. Despite a difference in the percent sub-clones showing new repeat species,
these data indicate that like MSH6-deficient DLD-1 cells, TET2-depleted HeLa cells
display MSI. I also examined the frequency of MSI in BM DNAs from aged WT or Tet2/-

mice. Tet2-/- BM samples showed 43-86% novel alleles at A33, Bat26, Bat66 and

D6Mit59 loci (Figure 37), while no novel alleles were detected at these loci in each of the
WT BM samples, further demonstrating Tet2 loss displays MSI.
To further confirm that the deletion of TET2 leads to the mutator phenotype, I
measured the spontaneous forward mutation frequency in the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) gene in TET2KD HeLa cells, control HeLa cells
(negative control) and DLD-1 cells (positive control). Human HPRT gene encodes HPRT
enzyme whose activity is important for DNA synthesis. 6-thioguanine (6-TG) is a toxic
nucleoside analog and it is used for cell selection. Cells without HPRT gene mutations
are poisoned by 6-TG, while HPRT gene mutations help cells survive and form colonies.
As shown in Figure 34, the mutation frequency in TET2KD HeLa cells had a 24-fold
increase compared to control HeLa cells and is ~10-fold lower than that in hMSH6deficient DLD-1 cells (Figure 34). The presence of HPRT mutations was confirmed in
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mutant clones of each cell type and most of the mutations were located at HPRT hot spots.
This is likely due to both the efficiency of TET2 knockdown and a likely TET2independent mechanism for MSH6-mediated MMR. Similar results were obtained using
control and Tet2-knock down NIH3T3 cells (Figure 35), confirming that TET2 loss
causes a mutator phenotype.
Lastly, I analyzed the number and type of mutations in a cohort of human MDS
cases. Interestingly, MDS patients with TET2 mutations harbor a significantly higher
number of mutational events compared to patients without TET2 mutations (Figure 39).
The association of the presence of TET2 mutations with higher mutational frequencies in
MDS patients is consistent with the findings that Tet2 loss constitutes genetic instability.
Collectively, these observations are consistent with the hypothesis that TET2 is likely
involved in recruitment of MSH6 to the chromatin, and TET2 loss impairs MMR in vivo
thereby enhancing susceptibility to malignant transformation by a multitude of genetic
mutations.

2.5 CONCLUSIONS
Studies using different Tet2 knock-out animal models have revealed that Tet2 loss
alters the epigenetic landscape with decreased 5hmC and global hypermethylation of the
DNA, increases HSC self-renewal and myeloid progenitor expansion with skewed
differentiation toward monocytic lineages, leading to the pathogenesis of myeloid
malignancies84. Here, I show that a fraction of Tet2-/- mice develop lymphoid
malignancies of both T- and B-cell origin, demonstrating that TET2 plays an important
role in both myeloid and lymphoid malignancies. Leukemogenesis is thought to be a
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multi-step process in which a series of genetic mutations may be acquired in a specific
clonal lineage. Genome analysis of Tet2-/- tumors allowed not only a better understanding
of Tet2 loss-mediated leukemogenesis, but also the identification of candidate secondary
gene mutations that lead to diverse disease phenotypes in Tet2-/- mice.
The exome sequencing identified numerous SNVs/indel in Tet2-/- tumors of each
cell origin, indicating that TET2 loss constitutes a state of genetic instability. The
increased susceptibility of mutational acquisition is likely further accelerated in Tet2-/HSC/HPCs since TET2-loss induced intrinsic changes in these cells, with increased selfrenewal and proliferation. TET2 loss represents an obvious initiating event in the
pathogenesis of hematological malignancies. The occurrence of secondary oncogenic
gene mutations, presumably in an early hematopoietic progenitor, is likely capable of
modifying the disease phenotype and/or promoting the transformation/progression of a
specific hematological malignancy in Tet2-/- mice. This is evident by the acquisition of
Notch1, Flt3, Nf1, Ebf1, Rhoa, Ikzf3 and other gene mutations in the Tet2-/hematological malignancies, consistent with the human hematological malignancy
induction and maintenance by gene alterations of these critical genes. Consistently,
clinical observations also suggest an initiating role for TET2 mutations in the
pathogenesis of hematological malignancies.
Analysis of the clonal architecture in CMML showed that TET2 mutations are
often the first detected oncogenic event134. As well, the prevalence of TET2 mutations is
higher in secondary than in de novo AMLs123. Furthermore, single-cell-derived colony
genotyping identified TET2 mutation as one of the earliest events in the accumulation of
genetic alterations that lead to the leukemic clone expansion. And, a recent exome
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sequencing study on angioimmunoblastic T-cell lymphoma showed that 68% of cases
had both TET2 and RHOA mutations, and TET2 mutations predated RHOA mutations in
most cases as RHOA mutations were specifically identified in tumor cells, whereas TET2
mutations were found in both tumor cells and non-tumor hematopoietic cells99.
The MMR maintains genome stability primarily by correcting base-base and small
indel mispairs generated during DNA replication. In mammalian cells, these mispairs are
recognized by MSH2-MSH6 and MSH2-MSH3 complexes, both of which are required
for MMR135,136. Tet2-/- tumors are associated with the acquisition of SNVs and small
indel, and a significantly more SNVs were observed in loci containing Tet2-dependent
active DNA demethylation, where Tet2 normally binds. MSH6 is a TET2, but not TET1,
binding partner and Tet2 loss causes a mutator phenotype--hallmark of MMR defects, as
evidenced by increased MSI and mutational frequencies at the cellular level. The data
strongly suggest that TET2 is required for MMR in vivo by regulating MSH6 distribution
on the chromatin. Therefore, the loss of TET2 could promote the local mutation rate in
these Tet2-dependent active DNA demethylation loci by losing MSH recruitment.
However, it is also possible that besides altering gene expression, the active DNA
demethylation process itself could protect genomic stability. Indeed, 5mC has been
shown to be a mutagen in tumor cells137.
Interestingly, Li et al (2013) recently showed that H3K36me3 and SETD2 are
required for MMR in vivo, since H3K36me3 recruits hMutS onto chromatin through
direct interaction with MSH6. Further studies are warranted to determine if H3K36me3
and/or SETD2 play a role in the TET2-mediated recruitment of MSH6. Of note, Tet2deficient cells that become MMR defective are not malignant per se, but since they
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display a consistent increase in mutational rate, they could accumulate driver mutations
in target genes leading to malignancies.
My results unveil a novel role for TET2 in the maintenance of genome integrity,
and provide significant insight into the mechanisms by which loss-of-function TET2
mutations causes diverse human hematological malignancies (Figure 40). These
important findings might aid the generation of new therapeutic approaches for these
hematological malignancies.
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Figure 14 Tet2-/- mice develop lethal lymphoid malignancies involving both T- and
B-cell lineages.
(A) Kaplan-Meier survival curve of WT (n = 67) and Tet2-/- (n = 198)
mice. (B) Pie charts show the percentage of hematological malignancies of myeloid-, Tor
B-cell origin in Tet2-/- mice (n = 198). (C) May-Grunwald Giemsa stained PB smears
prepared from a representative WT mouse and Tet2-/- mouse with T- or B-cell
malignancy.
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Figure 15 Tet2-/- mice with T-cell malignancy.
(A) The gross morphologies of lymph nodes, spleen, liver, and thymus from a
representative Tet2-/- mouse with T-cell malignancy. (B) Flow cytometric analysis of the
T-cell lineage (CD4/CD8) in BM, spleen and thymus of a representative Tet2-/- mouse
with T-cell leukemia/lymphoma and an age matched WT mouse. (C) H&E stained
histological sections of femurs, spleen and liver from a representative Tet2-/- mouse with
T-cell leukemia/lymphoma and an age matched WT mouse.
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Table 2.1 Phenotypic characteristics of T-cell malignancies developed in 7 Tet2-/mice.
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Figure 16 Tet2-/- mice with B-cell malignancy.
(A) The gross morphologies of lymph nodes, spleen and liver from a representative Tet2/mouse with B-cell malignancy. (B) Flow cytometric analysis of the B-cell lineage
(B220/IgM) in BM and spleen of representative Tet2-/- mice with B-cell
leukemia/lymphoma and an age matched WT mouse. The numbers indicate the percent
cells in each cell population. (C) H&E stained histological sections of femurs, spleen and
liver from a representative Tet2-/- mouse with B-cell leukemia/lymphoma and an age
matched WT mouse.
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Table 2.2 Phenotypic characteristics of B-cell malignancies developed in 9 Tet2-/mice.
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Figure 17 Lymphoid malignancies in Tet2-/- mice are transplantable to secondary
recipients.
(A) Tumor transfer schema. Spleen cells (1x106) from a WT mouse or Tet2-/- mice with
T- or B-cell lymphoma/leukemia were each injected into sub-lethally irradiated (600cGy)
CD45.1+/CD45.2+ F1 recipients. (B) Kaplan-Meier survival curve of sub-lethally
irradiated recipients (5 animals / donor) transplanted with spleen cells from a WT muse
or Tet2-/- mice with T- or B-cell lymphoma/leukemia. (C) Flow cytometric analyses on
the T-cell lineage (CD4/CD8) within the donor (CD45.2+) cell populations of peripheral
blood cells from a representative recipient receiving spleen cells from a WT mouse or a
Tet2-/- mouse with T-cell lymphoma/leukemia. Flow cytometric analyses on the B-cell
lineage (B220/IgM) within the donor (CD45.2+) cell populations of peripheral blood
cells from a representative recipient receiving spleen cells from a WT mouse or a Tet2-/mouse with B-cell lymphoma/leukemia. Data demonstrate that the recipients receiving
spleen cells from Tet2-/- mice with T- or B-cell lymphoma/leukemia developed diseases
similar to their respective donor mice.
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Figure 19 Acquisition of mutations in Tet2-/- tumors.
Selected recurrent gene mutations in Tet2-/- tumors involving myeloid-, B- or T-cell
lineages as identified by whole exome sequencing.
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Figure 20 Notch1 mutations were identified from Tet2-/- mice with T-cell malignancy.
Sanger sequence traces of 4 Tet2-/- T-cell tumors with heterozygous mutations in Notch1
are shown in the middle panel. The mutational locations are shown as red asterisks in the
mouse Notch1 protein schematic representation (upper panel). Notch1 gene mutations
identified by exome-sequencing and/or Sanger sequencing in 6 Tet2-/- T-cell tumors are
summarized in the lower panel.

76

A

Intergenic
TSS
3'-UTR
5'-UTR
Exon

15

10

5

Intron
0

B

5hmC Fold Enrichment
(Observed/Expected)

Figure 21 5hmC distribution and enriched regions with genomic features.
(A) Distribution of averaged 5hmC enrichment at all genes in WT and Tet2-/- LK cells.
(B) Association of 5hmC–enriched regions with genomic features in LK cells. The
percentage of 5hmC–enriched regions overlapping a defined genomic feature was
compared with the percentage expected to fall in that particular region by chance based
on the genomic coverage of that region. Values are expressed as fold change from
expected.
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Figure 22 Changes of 5hmC among the genes with different expression levels.
Gene expression values (RPKM) obtained from RNA-Seq were used to divide all the
genes into four groups: Highly expressed (top 25%), Intermediate Expressed (25-50%),
Lowly expressed (50-75%) and Non Expressed (below 75%). Distributions of averaged
5hmC enrichment at all genes of each group in WT and Tet2-/- LK cells are shown.
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Figure 23 Increased mutational frequency in loci marked by Tet2-dependent 5hmC.
Significantly greater frequencies of overall SNVs/indel (A, upper panel) or C to T (or G
to A) mutations (A, lower panel) within the loci with Tet2-dependent active DNA
demethylation, but not the regions with Tet2-dependent 5mC conversion to 5hmC or
Tet2-independent 5hmC modification. Example of a genomic view showing the
overlapping feature of Tet2-dependent active DNA demethylation, with Rccd1 mutations
(B).
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Figure 25 Dynamic changes of 5mC and 5hmC surrounding the mutation sites.
Akap12 mutational signature was characterized as CCG. Pie chart depicts the results of
bisulfite-Seq and TAB-Seq.
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Figure 26 Generation of Flag-V5 tag knock-in ES cells.
(A) Targeting strategy for Tet2:Tag allele ES cells. The targeting vector contained a Neo
cassette flanked by two FRT sites, followed by a 0.5 kb genomic fragment upstream of
the Tet2 start codon and an ATG/3xFlag/V5 sequence. A 2.2 kb 5′ and a 4.8 kb 3′ arm
genomic fragments were sub-cloned into the vector for gene targeting. Positive ES cells
were identified by Southern blot. Square bars indicate exons. E, EcoRI. S, ScaI. (B)
Southern blot of ES cell DNA digested with ScaI and hybridized with a genomic
fragment external to the 5’ arm displayed a WT band of 6.3 kb and recombinant band of
4.0 kb (left panel), and ES cell DNA digested with EcoRI and hybridized with a probe
external to the 3’ arm displayed a WT band of 10.0 kb and a recombinant band of 8.9 kb
(right panel). (C) Comparable WT Tet2 and Tag-Tet2 transcripts in Tet2:Tag ES cells.
Data reported as relative expression units to the WT Tet2 expression in WT ES cells
using ß-actin as internal calibrator.
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Protein

Size

No. of Peptide No. of Peptide (control)

TET2

220

78

0

OGT

110

2

2

MSH6

163

2

9

TOP2A
SIN3A

174
15

47
1

32
1

MSH2

104

1

BRCA1

199

RAD51

37

4
2

1
0
0

Table 2.3 Table of the most relevant proteins identified by mass spectrometry in the
purification of TET2-associated proteins using Tet2:Tag knock-in ES cells. Spectral
counts for each interacting protein are shown.
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Figure 27 Flag-TET2 is expressed as a 240kD protein and localized in the nucleus.
pcDNA3.1-hTET2 (TET2) or empty vector (Mock) was transfected into 293 cells using
Lipo3000 transfection reagent. (A) Schematic map of pcDNA3.1-hTET2 construct. (B)
Western blot was performed with cytosol and nuclear fractions using anti-Flag antibody.
A ~240kD band was detected in the nuclear fraction of TET2-transfected 293 cells, but
not Mock cells, which agrees with the calculated molecular mass of Flag-TET2 based on
its primary structure. (C) Cells were stained with anti-Flag antibody followed by the
orange-fluorescent second antibody and green-fluorescent conjugated anti-F-actin
antibody. The cells were then stained with DAPI (blue). Merged image artificially
expressed in pink indicating co-localization of Flag-TET2 with DAPI, but not F-actin.
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Figure 29 MSH6 co-immunoprecipitates with TET2 N-terminal.
MSH6 failed to bind to TET2M and TET2C in HEK293 cells overexpressing each Flagtagged TET2 fragments. Nuclear extracts were immunoprecipitated with anti-MSH6
antibody and probed with anti-FLAG or anti-MSH6 antibodies.
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Figure 30 Immunostaining identified TET2 and MSH6 co-localization.
MSH6 foci formation and MSH6-TET2 co-localization in HeLa cells.
Immunofluorescence was performed to determine nuclear distribution of MSH6 and
TET2. Cells were stained with anti-TET2 antibody followed by the red-fluorescent
second antibody and anti-MSH6 flowed by green-fluorescent second antibody. The cells
were then stained with Hoechst33342 (blue). Merged image artificially expressed in
yellow indicating co-localization of TET2 with MSH6 in the nuclear.
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Figure 31 TET2 and MSH6 co-localization at different cell cycle.
HeLa cells were synchronized at G1, S and G2/M phase using double thymidine block.
Immunofluorescence was performed to determine co-localization of MSH6 and TET2.
Cells were stained with anti-FLAG antibody followed by the red-fluorescent second
antibody and anti-MSH6 flowed by green-fluorescent second antibody. Merged image
artificially expressed in yellow indicating co-localization of TET2 with MSH6 in the
nucleus.
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Figure 32 Tet2 is not physically involved in MMR activity in vitro.
In vitro MMR assay using nuclear extracts isolated from WT or Tet2-/- BM cells.
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Figure 33 Knockdown of TET2 in HeLa cells using human TET2-specific shRNA.
Western blot and qPCR analysis showing the expression of TET2 protein and mRNA in
HeLa cells stably transfected with a scrambled shRNA or a TET2-specific shRNAs.
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Figure 34 Increased mutational frequency in TET2 knockdown HeLa cells.
(A) HPRT mutability in control- and shTET2-HeLa cells. Data presented as mean ± SD.
Fold increase in mutation frequency was calculated using the mutation frequency of
control NIH3T3 cells as a reference, and a t test was used to estimate a p value. (B) Low
density 6-TG survival assay indicating resistance of TET2 knockdown HeLa cells.
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Figure 35 Increased mutational frequency in shTet2-NIH3T3 cells.
(A) Western blot and qPCR analysis showing the expression of Tet2 protein and mRNA
in NIH3T3 cells stably transfected with a scrambled shRNA or a Tet2-specific shRNAs.
(B) HPRT mutability in control- and shTet2-NIH3T3 cells. Data presented as mean ± SD.
Fold increase in mutation frequency was calculated using the mutation frequency of
control NIH3T3 cells as a reference, and a t test was used to estimate a p value.
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Figure 36 MSH6 foci formation and localization in control- and shTET2- HeLa cells
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Figure 37 Analysis of PCR product patterns of microsatellite markers in bone
marrow cells from WT and Tet2-/- mice.
The appearance of novel length alleles of the A33, D6Mit59 loci is indicated (asterisk)
for each sample. The D1Mit62 CA-repeat locus was used as a negative control, as this
locus is stable. No alterations were found at this stable locus in both WT and Tet2-/samples.
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Figure 38 Analysis of PCR product patterns of two microsatellite markers in
control- and shTET2-HeLa cells.
The asterisk shows the clone exhibiting new repeat species.
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Figure 39 Mutation numbers in MDS patients with or without TET2 mutations.
Exome sequencing data from a cohort of human MDS patients were analyzed for the
number and type of mutations and were summarized as mean ± SD in groups with (n=5)
or without (n=5) TET2 mutations.
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Figure 40 Proposed model for loss of Tet2 induced hematological malignancies.
In wild type individuals, active DNA demethylation can be initiated by TET2-mediated 1)
left panel, TET2 catalyzes the hydroxylation of 5mC to 5hmC, followed by
AID/APOBEC mediated conversion from 5hmC to 5hmU, which can be further
recognized by TDG and repaired through BER pathway. 2) right panel, 5mC is
metabolized through deamination to T to generate T:G mismatch, followed mismatch
repair mechanism through TET2 recruited MSH2, MSH6 heterodimer complex, which
replace T back to C during DNA replication. In Tet2-/- individuals, the loss oxidative
enzymatic activity eliminate Tet2-mediated oxidative pathway; while 5mC can still be
converted to T. The newly generated T:G mismatch could not be repaired by MSH2,
MSH6 heterodimer because of the loss of Tet2. This may eventually lead to diseasecausing mutations.
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CHAPTER
TET2 REGULATES ADULT BRAIN NEUROGENESIS
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3.1 ABSTRACT
Previous studies that have mapped genome-wide 5hmC, have shown that 5hmC
distributes temporally and spatially during neurodevelopment61,118,119. Interestingly,
5hmC acquisition in these regions (5mC specific) is different than what would be
expected. There is no obvious correlation between 5hmC gain and 5mC loss in many
important neurodevelopment-related genes, therefore one could argue that 5hmC role in
gene regulation may be via a mechanism other than by transient oxidation in the brain118.
In 2011, a study found Tet1 overexpression in the dentate gyrus (DG) significantly downregulated the methylation levels of Bdnf and Fgf1b, highlighting the role of 5hmC in
neurogenesis117. In addition, several types of neurodevelopment and neurodegenerative
disorders have been found closely associated with 5hmC, such as Rett syndrome, Autism
spectrum disorder and Alzheimer’s disease. Because of the extensive roles of 5hmC and
TETs, several studies have explored TET proteins functions in neurogenesis117,121. There
is evidence that Tet1-/- mice exhibit robust loss (~45%) of NSCs in the SGZ compared
with WT mice, and neurospheres from Tet1-/- show growth defects. Microarray studies
have shown that many genes (Galanin, Ng2 and Ngb) that are involved in NSC
proliferation are down-regulated121. In addition, Tet1-/- mice show increased hippocampal
long-term repression and memory defects121.
Because DNA methylation is critical for postnatal neurodevelopment, 5hmC may
also be involved in 5mC dynamics during aging. I first assessed the abundance of 5hmC
in the subventricular zone of the lateral ventricles and there was a substantial overlap
between 5hmC+ and NeuN+ cells in the granule cell layer in the dentate gyrus of the
hippocampus, whereas I noted a significant decrease of Tet1 mRNA and increase of Tet2
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mRNA in an age-dependent manner. Also, I observed the down-regulation of 5hmC
abundance at both postnatal day 7 and adult age compared to WT. Furthermore, to
explore the function of Tet2 in adult neurogenesis, BrdU incorporation assay and
immunofluorescence staining were performed. Interestingly, Tet2 positively regulates
neural stem/progenitor cells proliferation and differentiation. As well, luciferase reporter
assay indicated that Tet2 regulates the methylation dynamics of NeuroD1 and Gfap
promoter regions. Consistent with these observations, mRNA levels of NeuroD1 and
Gfap were decreased in Tet2-deficient cells. These results suggest that Tet2 is positively
involved in adult brain neurogenesis through epigenetic regulation.

3.2 INTRODUCTION
Adult neurogenesis occurs in two germinal zones of the brain: the subgranular zone
(SGZ) in dentate gyrus of the hippocampus and subventricular zone (SVZ) within the
walls of the lateral ventricles. Adult neurogenesis can be regulated by many cellular
activities including neural stem cells (NSC)/neural progenitor cells (NPC) proliferation
and differentiation, fate determination, maturation and localization of newborn
neurons115,116. Since neurogenesis exists in these two regions, it is possible to postulate
that neurogenesis may regulate learning and memory. As well, adult neurogenesis can be
regulated by signaling pathways and epigenetic regulators116,138.
Ten-eleven translocation (TET) family proteins contain two key components: Fe (II)
and 2-oxoglutarate (2-OG) to catalyze oxidation of the methyl group of 5mC to
hydroxymethyl, formyl and carboxyl groups, which generate 5-hydroxymethylcytosine,
5-formylcytosine and 5-carboxylcytosine in an enzymatic activity-dependent manner39,65.

100

Studies that have mapped genome-wide 5hmC, have shown that 5hmC distributes
temporally and spatially during neurodevelopment61,118,119. For example, studies have
shown an age-dependent abundance and distribution of 5hmC in the cerebellum and
hippocampus. Interestingly, 5hmC acquisition in these regions is different than would be
expected. There is no strong correlation between 5hmC acquisition and 5mC loss in many
important neurodevelopment-related genes, therefore one could argue that 5hmC role in
gene regulation may be via a mechanism other than by transient oxidation in the brain118.
To better understand the role of 5hmC in the brain, more than 6000 differentially
hydroxymethylated regions (DhMRs) at different ages have been identified. These
DhMRs were only found in adult brain, from 6-week-old brain, but not in postnatal day 7
(P7) cerebellum, indicating long-term modification of 5hmC in the brain118,119. Although
the correlation of 5hmC abundance and gene transcription is still unclear, the enrichment
of 5hmC and loss of 5mC at gene bodies coincide with gene transcription activation119. In
fact, 5hmC regulation of neurogenesis was reported in 2011. Overexpression of Tet1 in
the dentate gyrus (DG) significantly down-regulated the methylation levels of Bdnf and
Fgf1b, highlighting the role of 5hmC in neurogenesis117. Several types of
neurodevelopment and neurodegenerative disorders have been found closely associated
with 5hmC, such as Rett syndrome, Autism spectrum disorder and Alzheimer’s
disease119,120,139,140.
Because of the extensive roles of 5hmC and TETs, several studies have explored
TET proteins functions in neurogenesis117,121. There is evidence that Tet1-/- mice exhibits
robust loss (~45%) of NSCs in the SGZ compared with WT mice, and neurospheres from

101

Tet1-/- show growth defects. Microarray studies have shown that many genes (Galanin,
Ng2 and Ngb) that are down-regulated during NSC proliferation121.
The TET2 gene is well-characterized in the hematological system, however, little is
known about its biological role in the nervous system. Considering the high abundance of
5hmC in the mouse adult brain, I tested the assumption of a critical role for Tet2 in the
adult brain and for changes in neural processes, by proposing to examine roles and
relationships of Tet2 in the nervous system using a Tet2 knockout mouse model.
To this effect, I answer the following three questions regarding to TET2 in nervous
system: 1) Does Tet2 loss alter 5hmC level in the brain? 2) Does Tet2 regulate the
proliferation and differentiation of NSCs? 3) What are the downstream targets of Tet2 in
the brain? First, I used Tet2-/- mouse models to examine the expression and localization
of Tet2 at an embryonic stage. Because of the association between 5hmC and Tet2, I also
measured 5hmC abundance in different brain tissues in the absence of Tet2. During NSC
proliferation, DNA methylation can remain with relatively long-lasting effects after
several rounds of cell division138. As another form of epigenetic mechanism, DNA
methylation indeed plays an essential role in regulating adult neurogenesis. Previous
studies on Methyl-CpG-binding domain 1 (MBD1) and methyl CpG binding protein 2
(MeCP2) indicated their binding methylated CpG capacity in the promoters, which
subsequently suppressed gene expression. Mice with Mbd1-deficiency showed decreased
neurogenesis and impaired cognition through behavior studies. The promoter of fgf2 was
hypomethylated, which led to decreased neuronal differentiation141. In another study,
when Mecp2 was down-regulated, abnormal maturation and synaptogenesis of granular
neurons were present. Also, MeCP2 may influence glia-specific gene expressions like

102

GFAP142. More recently, a DNA demethylation study of Tet1 showed that Tet1 is
involved in neuronal active DNA demethylation and gene expression in mouse dentate
gyrus117. And, although Tet2 has been shown to be involved in hematopoietic
malignancies, the expression of Tet2 is relatively high in the nervous system than
hematological system143.
Therefore, I used Tet2-/- mouse model to investigate whether Tet2 can regulate adult
neurogenesis. The loss of Tet2 increased the proliferation of NSC and decreased the
differentiation of NSC. Since DNA methylation is critical in postnatal neurodevelopment
and seems to undergo age-dependent changes in the brain, I collected and examined the
hippocampus and cerebellum of mice at postnatal day 7 (P7), 6 weeks and 1 year of age.
Proliferation and differentiation of NSC/NPC and the underlying molecular mechanisms
were examined to uncover the role of Tet2 in adult neurogenesis.

3.3 MATERIALS AND METHODS
3.3.1 Generation of Tet2-/- mice and LacZ staining
Tet2: LacZ KI mice were generated as previously described84. Briefly, the start
codon ATG was replaced by LacZ: GFP: Neo cassette. After crossing with Flipase
and/Cre mice, Tet2: LacZ and Tet2: GFP mouse models were obtained. The female mice
were euthanized according to The Guide and as required by IACUC protocol. Embryos
were collected from the uterus and extra tissues were removed in PBS. Embryos were
fixed in whole mount fixative for 40min on ice and rinsed 3 times (3X) in PBS for 15min
each. The fixed embryos were then stained by X-gal staining solution at 37°C O/N in the
dark, then rinsed in PBS for imaging.
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3.3.2 Adult NPCs isolation and culture
Neural progenitor cells were isolated from 6-week-old male WT and Tet2-/- mice.
Briefly, the dentate gyrus (DG) was dissected-out from coronal sections. Enzymatic
digestion was used to dissociate the cells. Dulbecco’s Modified Eagle Medium (DEME)
supplemented with 10% FBS, 2mM L-Glutamine and 1% P/S was added to each sample.
The cells were filtered through 70-μm cell strainer and washed with DMEM. The cells
were then loaded onto 50% Percoll for ultracentrifugation at 127k RPM fro 30 min at
20°C. NPCs fraction was cultured in DMEM supplemented with 20ng/ml FGF2,
20mg/ml EGF in a 5% CO2 cell culture incubator at 37°C.

3.3.3 Proliferation and differentiation analyses of cultured adult NPCs
Neural progenitor cells (between passage 4 to 10) were trypsinized and placed on
poly-L-laminin coated chamber slides. Each well contained about 50,000 cells and
complete DMEM medium supplemented with growth factors (FGF2 and EGF). 20 hours
after plating, the culture medium was supplemented with 5μM BrdU for an additional 8h.
NPCs were fixed with 4% paraformaldehyde solution (PFA) for 30min at room
temperature followed by 1M hydrochloric acid (HCl) for 30min at 37°C and then washed
by borate buffer for 30min, for immunohistochemistry. For NPCs differentiation, NPCs
were cultured with differentiation medium, DMEM with 5μM forskolin, 1μM retinoic
acid and 0.5% FBS. The NPCs were cultured by differentiation medium for 4 days in a 5%
CO2 cell incubator at 37°C for immunostaining later.
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3.3.4 Real-time PCR
Total RNA was purified from WT and Tet2 KO brain tissue using RNeasy kit
(Qiagen). The RNA was reverse transcribed to cDNA. RT-qPCR was performed in 20μl
aliquots with 10μl Fast SYBR Green Master Mix, 200nM forward and reverse primers
mix and 20ng cDNA. The triplicate reactions were applied to ABI 7500 Fast Real-Time
PCR System and quantified using SDS 1.4 software. The relative quantification of Tet2
mRNA was determined by threshold cycle value and normalized to the corresponding
value of mouse actin.

3.3.5 Confocal Microscopy and immunofluorescence analysis
The protocol has been described in the previous chapter. Briefly, cells were grown
in 6-well plates on coverslips. Growth medium was aspirated and cells were fixed with 4%
formaldehyde in PBS for 15 min at room temperature. Then, the fixative was discarded
and the cells were rinsed with PBS 3 times. The cells were incubated by blocking buffer
for 60min and then incubated with primary antibody overnight at 4°C. The primary
antibody was removed and fluorochrome-conjugated secondary antibody was added to
the specimen for 1h at room temperature in the dark. Coverslips were mounted by DPAI
associated mount reagent and observed by fluorescence microscopy.

3.3.6 Dot blot
Genomic DNA was isolated from NSC harvested from WT and Tet2-/- hippocampus
and denatured by 0.2N NaOH. Samples were dotted on nitrocellulose membrane. After
cross-linking by ultraviolet, the membrane was blocked in 10% nonfat milk and 1%
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bovine serum albumin (BSA). The primary antibody anti-5hmC and secondary antibody
HRP-conjugated goat anti-mouse were incubated with membrane, respectively. Signals
were detected by ECL detection system as described in the previous chapter.

3.3.7 DNA plasmids and luciferase assay
NeuroD1 and Gfap promoter regions were amplified by PCR from mouse brain
cDNA. The PCR products were cloned into pGL3 and confirmed by Sanger sequencing.
Human elongation factor 1a promoter region served as an internal control. 2x106 NPCs
were trypsinized and mixed with plasmids, and then applied to electroporation. The cells
were placed into proliferation medium and differentiation medium for 24h and 48h,
respectively. The cells were then lysated and collected for luciferase assay. About 20μl
cell lysate was mixed with 100μl Luciferase assay buffer II. F-luc activity was measured
by SpectraMax M2E plate reader and the mixture was stopped using Glo Buffer with
substrate. After normalization with R-luc, the transfection efficiency was calculated
based on a commercial manual (Promega).

3.3.8 Statistical analysis
To determine differences between experimental groups, I used the Student’s t-test or
analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests as
appropriate. P values < 0.05 were considered significant.
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3.4 RESULTS AND DISCUSSION
3.4.1 TET2 is highly expressed in the central nervous system
Since DNA methylation is critical for postnatal neurodevelopment in an agedependent manner, 5hmC may also be involved in 5mC dynamics during aging. To
address these issue, I assessed the abundance of 5hmC in anterior regions of the
subventricular zone (SVZa), a region of high neurogenesis, and rostral migratory stream
in olfactory bulb (RMS-OB) using 5hmC specific antibody. This procedure allowed me
to discover the most active neurogenesis regions with 5hmC positive cells, which also
helped to define the regions to be studied in the future. Immunohistochemistry of 5hmC
in these regions showed no significant co-localization between 5hmC positive cells and
NeuN positive cells in SVZa (Figure 41). However, in the granule cell layer (GCL), there
was a substantial overlap between 5hmC+ and NeuN+ cells, suggesting 5hmC is required
for neurodevelopment. Because TET family proteins catalyze the oxidation of 5mC to
5hmC37, I speculated that Tets may be required for 5hmC dynamics during
neurodevelopment. A significant decrease of Tet1 mRNA levels was seen during aging
from P7 to 6 weeks old, in the cerebellum, whereas an increase in Tet2 mRNA levels
occurred during aging (Figure 42). Together, the data suggest that both 5hmC and Tet2
are required for age-dependent neurodevelopment.
To determine genome-wide Tet2 function and 5hmC distribution during
neurodevelopment and aging, I used a Tet2 knockout mouse model that had been
previously generated in Dr. Mingjiang Xu’s lab. To examine the localization of Tet2 in
vivo, LacZ-GFP-Neo lines was mated with Flipase mice to acquire LacZ-GFP line. The
embryos of Tet2: LacZ were collected at embryonic day 13.5 (E13.5) and stained with
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regular β-gal (Figure 43). Despite some staining variability between embryos, the LacZ
expression was observed in both the cerebellum and spinal cord suggesting a potential
role for Tet2 in neural cells.
To further confirm the elimination of Tet2 in Tet2 knockout mouse models, I
collected the brains of Tet2: GFP. The brain tissue was disrupted and total RNA was
purified from it. After reverse transcription, cDNA of Tet2: GFP was applied to RTqPCR to examine relative Tet2 expression. Five primers were designed, which aimed at
exon3, 4, 6 and 11 (Figure 44). Clearly, Tet2 was completely lost at ATG region exon3
and exon4. However, there was still low abundance of the last several exons that may be
due to the different splicing forms of Tet2.
Although I did not see developmental defects in Tet2-/- mice, the role of Tet2 in adult
functioning still needs to be elucidated. Given the high abundance of 5hmC in mouse
brain, it is reasonable to propose a regulatory function for Tet2-mediated 5mC oxidation
in adult neurogenesis. To determine whether Tet2 deficiency affects 5hmC dynamics, I
compared the abundance of 5hmC of WT and Tet2-/- mice cerebellum. At P7, 5hmC in
Tet2-/- samples decreased to half of the amount of 5hmC in WT samples. In adults, 5hmC
in Tet2-/- samples decreased to 3/4 of the amount of 5hmC in WT samples (Figure 45).
This suggests that Tet2 is required for 5hmC dynamics in both P7 and adults.

3.4.2 Hydroxylation of 5-methylcytosine affects stem cell proliferation and
differentiation in dentate gyrus of the hippocampus
To explore the function of Tet2 in adult neurogenesis, I examined the expression
pattern of 5hmC in the dentate gyrus of adult hippocampus. I isolated adult NPC from
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dentate gyrus of WT and Tet2-/- mice. As shown in (Figure 46), all cultured adult NPCs
showed positive Nestin and Sox, which are the markers for progenitor cells. It is feasible
to use these cells for molecular and functional analyses because of their homogeneity. I
then examined the proliferation of these NPCs by exposing the cells to BrdU for eight
hours. It is obvious that Tet2-/- NPCs exhibited 1.5 fold BrdU incorporation compared to
that in WT NPCs.
To determine the effect of Tet2 on NPC differentiation, both WT and Tet2-/- DG
NPCs were exposed to differentiation medium for three days. Several independent assays
were performed to investigate the phenotypes of WT and Tet2-/- NPCs differentiation
(Figure 47). I first stained the differentiated cells with β-III tubulin (Tuj1) and glial
fibrillary acidic protein (GFAP) (Figure 48). Tuj1 and GFAP are specific cell markers for
neurons and astroglia, respectively. In addition to WT NPCs, Tet2-/- NPCs were also able
to differentiate to neurons and astrocytes. Interestingly, Tet2-/- NPCs showed a 70%
decrease in neuronal cell differentiation and a 50% decrease in astrocyte differentiation
compared with WT NPCs. These data indicate Tet2 negatively regulate NPC proliferation
but positively regulate NPC differentiation.

3.4.3 TET2 regulates the expression of NeuroD and GFAP transcriptionally
The

downstream

targets

of

Tet2

are

still

unknown.

To

validate

the

immunocytochemical results, I tested the assumption that two neural cell markers may be
altered by Tet2 deletion: neurogenic differentiation 1 (NeuroD1) and GFAP. NeuroD1 is
a pan-neuronal transcriptional activator, which contributes to transcriptional regulation of
neurogenesis. GFAP is an astrocyte specific cell marker during development. The
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NeuroD1 and Gfap promoters were cloned upstream of luciferase reporter construct,
allowing the detection of transcriptional features of these neural factors. Cells lysates
were mixed with luciferase substrate and measured by luminometer. As I expected, the
deletion of Tet2 suppressed the Luc activity at 48h post-transfection. Little luciferase
expression was shown in Tet2-/- cell lysate. Furthermore, the relative mRNA expression
of NeuroD and Gfap in Tet2-/- NSC were much lower than that in WT NSC (Figure 49).
Taken together, these data suggest that Tet2 is capable of regulating NeuroD and Gfap
expression through promoter suppression.

3.5 CONCLUSIONS
TET family proteins have been well-studied recently, especially their enzymatic
function in active DNA demethylation39. However, the physiological function of Tet2 in
neural systems remains unknown. Although no significant development defects were
observed in Tet2-/- mice from previous reports84, my data indicates a transcriptional
regulatory role for Tet2 in adult neurogenesis.
To determine if the transcription levels of Tets change during postnatal development
and aging, I measured Tet1, Tet2 and Tet3 mRNA levels at two different ages, P7 and 6
weeks of age. I observed a remarkable decrease of Tet1 mRNA and increase of Tet2
mRNA during aging, suggesting potential opposite functions of Tet1 and Tet2 during
postnatal development. Indeed, I found that Tet2 was expressed in the brain and spinal
cord from Tet2:LacZ mouse models. Immunostaining of 5hmC showed Tet2 regulates
5hmC abundance preferentially in SGZ rather than SVZ. Finally, I found that overall,
5hmC abundance was decreased in both Tet2-/- proliferating cells and Tet2-/-
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differentiating cells, suggesting that the loss of Tet2 impairs the oxidation of 5mC and
subsequently influences NPC proliferation and differentiation. I also examined
proliferation and differentiation of WT and Tet2-/- NPCs in vitro. Loss of Tet2 leads to
decreased neuronal differentiation and glial differentiation. I speculated these cellular
phenotypes might be induced by the alterations of neural-related transcription factors,
which results from the hypermethylation in their promoter regions. Notably, I found two
genes NeuroD1 and GFAP mRNAs were reduced and their promoter activities were
decrease in Tet2-/- cells. Therefore, it is possible that during adult neurogenesis, Tet2
regulates the gene’s promoter region and catalyzes the oxidation of 5mC, which allows
the transcriptional activation of the genes and balances neuronal and glial cell numbers.
In summary, I characterized Tet2 and 5hmC in mouse cerebellum and hippocampus
during postnatal development and aging. Tet2 regulates 5mC oxidation at NeruoD1 and
Gfap promoter regions during aging, pointing to a critical role for Tet2 in adult
neurogenesis. My study has great potential to improve the understanding of Tet2mediated DNA demethylation in neurodevelopment and neurodegenerative disorders.
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A

B

Figure 41 Immunostaining of 5hmC in two brain regions in mice.
(A) 5hmC specific immunostaining in 6-week old anterior regions of subventricular zone.
(B) 5hmC specific immunostaining in 6-week old olfactory bulb.
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Figure 42 Tet1, Tet2 and Tet3 expression levels in P7 and 6-week old cerebellum.
Quantification of Tet1, Tet2 and Tet3 mRNA levels in different individuals (A&B) (n = 3,
mean ± SEM.; *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA)
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Figure 43 Tet2 is expressed in the nervous system.
(A) Gene targeting strategy. Exons are filled boxes and LacZ-GFP-Neo cassette was
introduced into Tet2 start codon region. (B) LacZ staining of Tet2:LacZ embryos
showing Tet2 expression in the brain and neural tube.
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Figure 44 Detection of Tet2 in WT and Tet2-/- hippocampi.
(A) Schematic of real-time PCR primers used to detect Tet2 mRNA. (B) The sequences
of real-time PCR primers. (C) Real-time PCR analysis of Tet2 mRNA levels in the brain.
Actin was used for sample normalization.
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B

Figure 45 Quantification of 5hmC in P7 and adult cerebellum.
(A) Measurement of 5hmC in genomic DNA from P7 and adult cerebellum by dot blot
using anti-5hmC antibody. (B) 5hmC quantification of (A).
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Sox2

DAPI

Merge

Figure 46 Cultured adult neural progenitor cells expressed representative cell
markers. Nestin (cytoplasmic, red) and Sox2 (nuclear, green; DAPI in blue).

117

C

Figure 47 Quantification of 5hmC in proliferating and differentiating cells from WT
and Tet2-/- adult NPCs.
(A) NPCs were harvested from WT and Tet2-/- mice with splenomegaly. (B) Detection of
5hmC in adult NPCs from WT and Tet2-/- mice. (C) 5hmC dynamic changes in
proliferating cells and differentiating cells from WT and Tet2-/- adult NPCs.
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A

B

C

Figure 49 The NeuroD1 and Gfap promoter regions are altered by Tet2.
(A) The NeuroD1 and Gfap promoter regions were cloned into luciferase reporter
constructs. (B) Luciferase reporter assay showed decreased NeuroD1 and Gfap promoter
activities in Tet2-/- differentiating NPCs. Renilla luciferase (R-Luc) plasmid served as a
transfection control. Real-time PCR showed that Tet2-/- NPCs had
decreased NeuroD1 mRNA levels (n = 3, p<0.05), and decreased Gfap mRNA levels (n
= 3, p<0.05) upon differentiation. The relative mRNA levels were in comparison with
Gapdh mRNA.
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CHAPTER
CONCLUSIONS AND FUTURE DIRECTIONS
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Studies using different Tet2 knock-out animal models revealed that Tet2 loss alters
the epigenetic landscape with decreased 5hmC and global hypermethylation of the DNA,
increases HSC self-renewal and myeloid progenitor expansion with skewed
differentiation toward monocytic lineages, leading to the pathogenesis of myeloid
malignancies84. Identification of critical novel partners of TET2, and unveiling the
functional significance of their interactions may provide valuable insights into the
mechanisms that underlie critical roles of TET2 in the tumorigenesis of many cancers.
In this dissertation I investigated whether Tet2 loss leads to various types of
hematological malignancies other than myeloid malignancies, and what cellular
phenotypes Tet2-/- mice may have. Because clinical studies have reported the
haploinsufficient role of TET2 in leukemic patients, it was important to understand if
Tet2 loss in mice causes leukemic disease phenotypes as in humans. Using a two-year
follow-up investigation, I found that Tet2-/- mice also develop lymphoid malignancies,
consistent with TET2 mutant patients with lymphoid disorders. Hence, additional genetic
lesions is at least in part required for Tet2 loss induced hematological malignancies.
Depending on the methods in genome analysis, diverse Tet2-/- genome landscapes
can be depicted via next-generation exome sequencing and aCGH. These techniques
make it possible to sequence all the protein-coding genes and detect chromosome
abnormalities. Therefore, it was feasible to propose understanding if Tet2 is required for
maintaining genome integrity. By using exome sequencing, several “driver mutations”
were identified in Tet2 loss background. Because of the biological instability of 5mC, it
is plausible to assume that these mutation sites are close to Tet2-dependent 5hmC sites.
Indeed, significant correlations between mutation sites and Tet2-dependent 5hmC sites
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were found. Next, if Tet2 regulates genome integrity, relying on its enzymatic activity,
mutation sites would be expected to be located only at cytosine. Then, it would be
important to understand what are the TET2 protein interactors that participate in Tet2mediated DNA repair mechanism. The present finding that there is a TET2 and MSH6
interaction, strengthen the concept of mutator phenotypes in Tet2-/- mice and TET2
knockdown cell lines. With these observations, a model was proposed that explains how
Tet2 can regulate genome integrity through interacting with MSH6. Chapter II
determined that:


~8% of Tet2-/- mice develops lymphoid malignancies of both T- and B-cell origin,
although myeloid malignancies dominates.



Whole-exome sequencing identified recurrent mutations from Tet2-/- tumors of
each cell origin, such as Notch1 mutations in the T-cell leukemia/lymphoma.



Using protein purification and mass spectrometry, I found that TET2 associates
with MSH6, a key protein involved in DNA-mismatch repair (MMR).



Tet2-depleted HeLa, and NIH3T3 cells display elevated spontaneous mutation
frequency, characteristic of MMR-deficient cells.

Also, I characterized Tet2 and 5hmC in mouse cerebellum and hippocampus during
postnatal development and aging. Tet2 regulates 5mC oxidation at NeruoD1 and Gfap
promoter regions during aging, pointing to a critical role for Tet2 in adult neurogenesis.
My study has great potential for improving the understanding of Tet2-mediated DNA
demethylation in neurodevelopment and neurodegenerative disorders. Chapter III
determined that:
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Tet2 is highly expressed in adult brain compared to postnatal P7 brain.



Loss of Tet2 leads to increased adult NPCs proliferation and decreased adult
NPCs differentiation.



Tet2 regulates adult brain neurogenesis through 5mC oxidation of NeuroD1 and
Gfap promoter regions.
Together, the observations presented here reveal that Tet2 is involved in different

regulatory mechanisms in different systems. In the hematological system, Tet2 serves as
a tumor suppressor gene to protect the genome from being mutated and is also dependent
on the interaction with MSH6 during DNA damage repair. In the nervous system, it is
also clear that Tet2 regulates 5hmC dynamics at its specific downstream loci, and
subsequently has an effect on adult neurogenesis. A better understanding of Tet2
regulatory network including TET2-binding protein complex and Tet2-binding DNA
sequences may prove to be essential for pharmaceutical research, with the goal, to
address Tet2–related diseases.
Future research on Tet2 in the hematological system will be focused on several
important aims: 1) providing a detailed characterization of hematological malignancies of
Tet2-/- mice; 2) determining when mutations occur during cell differentiation; 3) mapping
the minimum binding regions between TET2 and MSH6; 4) crossing Tet2-/- and Msh6-/mice to elucidate the relationship between TET2 and MSH6. Additional questions to be
addressed include whether the association between TET2 and MSH6 is disrupted in Tet2deficient mice; and if genomic instability is a “driver” or a “consequence” of malignant
transformation. The latter could be clarified by exome sequencing of premalignant WT,
Tet2+/- and Tet2-/- hematopoietic stem/progenitor cells.
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For understanding the role of Tet2 in neurogenesis, it makes sense to evaluate
Tet2 in the context of spatial learning and memory based on the present findings of
impaired neurogenesis in Tet2 mutants, which may greatly influence learning and
memory. I can also investigate the epigenetic changes (5mC and 5hmC) of Tet2
downstream target genes and examine their transcriptional regulation and involvement in
neurogenesis. The definitive role of Tet2 loss-induced adult-neurogenesis-defects should
be investigated using Tet2 conditional knockout mice in which tissue/cell-specific
elimination would help to better understand the biological functions of Tet2 in the
nervous system.
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